Small molecule degrading methods for treating ALS / FTD

Small molecule therapeutics targeting r(G4C2)n repeats in ALS/FTD provide an effective alternative to ASOs by enhancing tissue penetration and reducing RNA repeat abundance and associated pathology, offering a promising treatment for ALS/FTD.

JP2024541938AInactive Publication Date: 2024-11-13UNIV OF FLORIDA RESEARCH FOUNDATION INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525014
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-27
Filing Date
2022-10-27
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapeutic methods for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are limited by low tissue penetration and distribution of antisense oligonucleotides (ASOs), requiring intrathecal administration and causing discomfort, while small molecules offer a promising alternative due to their biologically available and orally accessible nature.

Method used

Development of small molecule therapeutics, such as pyridocarbazole compounds with a linker group carrying an RNase recruitment moiety, that bind to and enzymatically degrade RNA sequences containing hexanucleotide repeats (r(G4C2)n, reducing their abundance and associated pathology.

Benefits of technology

The small molecule compounds effectively reduce RNA repeat abundance, inhibit RAN translation, and alleviate downstream pathology in ALS/FTD by selectively targeting and degrading r(G4C2)n repeats, demonstrating efficacy in patient-derived cell and animal models without significant toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541938000001_ABST
    Figure 2024541938000001_ABST
Patent Text Reader

Abstract

r(G4C2) in chromosome 9 open reading frame 72 is involved in amyotrophic lateral sclerosis and frontotemporal dementia (ALS / FTD) exp Small molecule embodiments, i.e., ALS compounds, that bind to RNA repeat expansions are described. These ALS compounds include a pyridocarbazole moiety having at least one substituent and an RNase recruiting moiety linked to the pyridocarbazole moiety by a polyethylene glycol group.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Government support statement This invention was made with Government support under Grant Nos. NS096898, NS099114 and NS116846 awarded by the National Institutes of Health. The Government has certain rights in this invention.

[0002] Electronic Sequence Listing Reference The entire contents of the electronic sequence listing (U120270103WO00-SEQ-JDH.xml; size: 55,627 bytes; creation date: October 27, 2022) are incorporated herein by reference. [Background technology]

[0003] RNA repeat expansion diseases are characterized by short repeated sequences of RNA and are implicated in over 30 human diseases, the majority of which are neurodegenerative in nature. 1 Some of these diseases are considered incurable by today's standards. The pathogenesis of these RNAs results from the formation of disease-specific RNA structures (most commonly hairpin structures) that are formed from repeat RNAs and are absent in transcripts lacking these repeats. 2 These structures disrupt classical cell biology, affecting processes such as pre-mRNA processing, RNA / protein complex formation, and translation. 2,3 .

[0004] One such disease is C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), collectively referred to as c9ALS / FTD. The genetic contribution to this disease is due to a hexanucleotide repeat expansion found in the first intron of chromosome 9 open reading frame 72 (C9orf72), namely GGGGCC[r(G4C2) exp can be traced to 4,5This r(G4C2) repeat expansion is involved in the majority of familial c9ALS / FTD cases, and this repeat is considered to be the major genetic cause of c9ALS / FTD. 4,5 Therefore, there is a great need for novel therapeutic approaches to target and reduce this repeat expansion. Antisense oligonucleotides (ASOs) are currently available that target r(G4C2) exp Although they offer state-of-the-art therapeutic intervention for cancer, ASOs generally have poor tissue penetration and distribution 6~9 Furthermore, ASOs must be administered intrathecally, increasing the risks and discomfort to patients during treatment. 10 Small molecules therefore offer an attractive alternative to ASOs, as their low molecular weight makes them both biologically and orally available. 11,12 .

[0005] Typically r(G4C2) repeats longer than 30 exp contributes to c9ALS / FTD pathology through two major mechanisms: 1) sequestration of RNA-binding proteins, specifically heterogeneous nuclear ribonucleoprotein H (hnRNP H), and 2) initiation of repeat-associated non-AUG (RAN) translation. 4,13~19 The hairpin structure formed by the hexanucleotide repeat creates a 1x1GG internal loop that sequesters hnRNP H, leading to the formation of nuclear foci and disruption of pre-mRNA processing (i.e., retention of intron 1). 11,19,20 These foci then disrupt nucleocytoplasmic transport, further contributing to the pathology of c9ALS / FTD. In addition to the toxicity caused by these mechanisms, RAN translation produces toxic dipeptide repeat (DPR) proteins that contribute to neuronal cell death. 19,21,22 .

[0006] Thus, one object of the present invention is to provide a method for the preparation of r(G4C2) in cells. exp The goal is to develop small molecule therapeutics that reduce abundance, providing an attractive therapeutic approach to alleviate downstream pathology in c9ALS / FTD. Summary of the Invention

[0007] The present invention relates to methods for the treatment of ALS / FTD. Aspects of the methods relate to ALS compound embodiments capable of binding to and inducing enzymatic degradation of RNA sequences transcribed from microsatellite G4C2 repeats in the C9ORF72 genotype. ALS compound embodiments include, in part, polycyclic heteroaromatic compounds, specifically pyridocarbazole moieties. These embodiments further include at least one substituent attached to the pyridocarbazole moiety that includes a linker group carrying an RNase recruiting moiety. In particular, ALS compound embodiments include pyridocarbazole RNase recruiting compounds of formula I, where R is hydrogen or C1-C3 alkyl, preferably methyl or hydrogen, more preferably hydrogen; n is an integer from 1 to 6, preferably 4; and Y is -COO- or -CHO-, preferably -CHO-. [ka] The ALS compound of formula I may be viewed as having two functional groups, the r(G4C2) repeat binding functional group and the RNase recruitment functional group, which are attributed to the carbazole core of formula II, where X may be hydroxyl. [ka] The RNase recruitment functionality is attributed to the phenoxythiophenone moiety of formula IIIA. When R" is hydrogen and R' is an alkyl or other non-hydrogen group, the active form of formula IIIA is obtained. When R" is an alkyl or other non-hydrogen group and R' is hydrogen, the inactive form of formula IIIA is obtained. The phenoxythiophenone moiety of formula IIIA is attached at its R' position to the carbazole core of formula II at X via a PEG-amide linker of formula IV. Combination of formula IIIA and formula IV gives the RNase linker of formula IIIB. [ka]

[0008] While all Y, R and n forms of the ALS compounds of formula I provide the biological activity described herein, preferred composition embodiments of the invention include ALS compounds of formula I where Y is -CHO-, R is hydrogen, and n is 2. Pharmaceutically acceptable salts of the composition embodiments of formula I are also included as aspects of the invention.

[0009] Further embodiments include the ALS compound as r(G4C2) m where m is an integer designator between 24 and 1,000, and exp These embodiments include methods for complexing and / or binding with an abnormal number of RNA repeats, where m is at least 100, preferably at least 200, more preferably at least 500 to at least 1000. In these embodiments, the RNA repeat sequence is at least an RNA hairpin structure.

[0010] Further embodiments include, but are not limited to, methods in which the RNA repeat is present in cells such as cell cultures, HEK293T cells transfected to express the RNA repeat expansion, ALS patient-derived cells, lymphoblastoid cells, induced pluripotent stem cells (c9 iPSC cells) and iPSC-derived spinal cord neuron cells (c9 iPSN). The RNA repeat may also be present as c9ALS / FTD BAC cells in transgenic mice. RNA repeat r(G4C2) exp The authors found that these cells contained chromosome 9 open reading frame 72, known as C9orf72, and an abnormal repeat called r(G4C2) located within intron 1 of C9orf72. exp may be present and transcribed in these cells.

[0011] An embodiment of the method is characterized in that the ALS compound as formula I inhibits r(G4C2) expIt is also possible to reduce and / or inhibit RNA translation of the RNA. Furthermore, these methods preferably do not inhibit the transcription of C9orf72.

[0012] The present invention further includes a pharmaceutical composition comprising an ALS compound and a pharma- ceutically acceptable carrier. Preferably, the ALS compound comprises Formula I. More preferably, the ALS compound of Formula I has the designation n as 4. Preferably, the pharmaceutical composition comprises an effective amount, preferably an effective dose, of the ALS compound for the treatment of ALS / FTD disease.

[0013] The embodiments of the present invention also include methods of treating patients suffering from ALS / FTD. These embodiments include administration of an effective amount of an ALS compound of formula I, preferably with the designation n as 4. These embodiments also include administration of a pharma- ceutically acceptable composition comprising an effective amount or dose of an ALS compound of formula I. Preferably, the routes of administration include oral, intraperitoneal (ip), intravenous (iv), intramuscular (im), subcutaneous (SC), oral, rectal, intravaginal, intrathecal and / or intradermal. Preferably, the disease is amyotrophic lateral sclerosis.

[0014] Further embodiments of the present invention include methods for the treatment of other diseases caused by r(G4C2)RNA repeat expansion. ALS and FTD are the two extremes of a disease spectrum associated with this repeat expansion, which includes a wide range of neuropsychological disorders such as cognitive impairment, behavioral disorders and several other manifestations. All of these diseases can be treated as described herein for the treatment of ALS / FTD and the ALS-FTD disease spectrum. See, e.g., MBLeko et al., Behav, Neurol., v. 2019, Jan. 15, 2019, 2909168. [Brief description of the drawings]

[0015] [Figure 1]1A-1C show how monomeric small molecules target r(G4C2)exp. FIG. 1A shows the structure of small molecule binding compound 1 (compound of formula II, labeled as 1) that binds to r(G4C2)exp. Formula II (compound 1) has previously been reported to selectively bind to the G:G loop. FIG. 1B shows the structures of the ALS compound of formula I (hereinafter ALSFI, labeled as 2, also referred to herein as RIBOTAC2, hereinafter compound 2) and a negative control (compound 3, in which the RNase recruitment moiety of formula IIIA is attached to the linker moiety of formula IV at R″ instead of R′). The use of the R″ position of formula IIIA as the attachment moiety of the linker of formula IV results in a less active positional isomer of the RNase L recruitment module or recruitment moiety of formula IIIA. FIG. 1C is a schematic of the mechanism of action of ALSFI and the lack of action in the case of compound 3 (use of the inactive binding site R″ of formula IIIA). [Diagram 2]Figure 2A-E show that ALSFI (labeled 2) reduces c9ALS / FTD pathology in patient-derived lymphoblastoid cells. Figure 2A is a schematic of repeat-associated non-AUG(RAN) translation producing a toxic dipeptide repeat (DPR) protein that occurs when r(G4C2)exp is present within intron 1 of C9orf72. Figure 2B shows that ALSFI (labeled 2) dose-dependently reduces poly(GP) abundance as measured by electrochemiluminescence sandwich immunoassay in c9ALS patient-derived lymphoblastoid cells (LCLs) (n=3 C9orf72 LCLs, 3 repeats per cell line). Figure 2C shows a schematic of the alternative splicing isoform of C9orf72 resulting from retention of C9orf72 intron 1. Arrows indicate the location of the three RT-qPCR primer sets (intron 1 primer, exon 2-3 primer, and exon 1b primer) used throughout these studies. Figure 2D shows that ALSFI (labeled 2) dose-dependently reduces C9orf72 intron 1 abundance as measured by RT-qPCR (n=3 C9orf72 LCL cell lines, 3 replicates per cell line). Figure 2E shows that competitive binding of ALSFI (labeled 2) with the carbazole core binder of formula II (labeled 1, i.e., compound 1 in Figure 1A) as measured by RT-qPCR demonstrates that ALSFI and the carbazole core binder of formula II share the same target in cells (n=1 C9orf72 LCL, 3 replicates per cell line). Solvent indicates 0.1% (v / v) DMSO. *P<0.05, **P<0.001, ***P<0.0001, ****P<0.0001 as determined by one-way ANOVA with multiple comparisons (Figures 2B, 2D, and 2E). Error bars represent SD. [Diagram 3]Figure 3A-F show that ALSFI (labeled 2) reduces c9ALS / FTD pathology in patient-derived iPSCs and differentiated motor neurons. For all panels, the solvent shows 0.1% (v / v) DMSO. *P<0.05, **P<0.001, ***P<0.0001, ****P<0.0001 as determined by one-way ANOVA with multiple comparisons. Error bars indicate SD. Figure 3A shows that ALSFI (labeled 2) dose-dependently reduces poly(GP) abundance in c9ALS patient-derived iPSCs as measured by electrochemiluminescence sandwich immunoassay (n=4 C9orf72 iPSC cell lines, 3 replicates per cell line). Figure 3B shows that ALSFI (labeled as 2) dose-dependently reduces C9orf72 intron 1 abundance as measured by RT-qPCR (n=4 C9orf72 iPSC cell lines, 3 replicates per cell line). Figure 3C shows that ALSFI (labeled as 2) dose-dependently reduces C9orf72 exon 2-3 abundance as measured by RT-qPCR (n=4 C9orf72 iPSC cell lines, 3 replicates per cell line). Figure 3D shows that ALSFI (labeled as 2) dose-dependently reduces poly(GP) abundance in c9ALS motor neurons differentiated from patient-derived iPSCs as measured by electrochemiluminescence sandwich immunoassay (n=1 C9orf72 motor neuron cell line, 3 replicates per cell line). Figure 3E shows that ALSFI (labeled 2) dose-dependently reduces C9orf72 intron 1 abundance as measured by RT-qPCR (n=1 C9orf72 motor neuron cell line, 3 replicates per cell line). Figure 3F shows that ALSFI (labeled 2) dose-dependently reduces C9orf72 exon 2-3 abundance as measured by RT-qPCR (n=1 C9orf72 motor neuron cell line, 3 replicates per cell line). [Figure 4]Figures 4A-E disclose that ALSFI (labeled 2) removes r(G4C2)exp from c9ALS patient-derived iPSCs by an intrinsic degradation mechanism. Solvent indicates 0.1% (v / v) DMSO. *P<0.05, **P<0.001, ***P<0.0001, ****P<0.0001 as determined by unpaired t-test with Welch's correction (Figures 4B-E). Error bars represent SD. Figure 4A shows a schematic of nuclear exosomes involved in endogenous 3'-5' RNA degradation (left) and RNase L-induced cleavage of r(G4C2)exp (right). FIG. 4B is a graph showing that knockdown of nuclear exosome (hRRP6), RNase L or both hRRP6 and RNase L activity by targeted siRNA treatment results in loss of C9orf72 intron 1 degradation when co-treated with ALSFI (labeled 2) (n=1 iPSC cell line, 5 replicates per cell line). FIG. 4C shows that knockdown of nuclear exosome (hRRP6) activity by targeted siRNA treatment does not affect C9orf72 exon 2-3 abundance when co-treated with ALSFI (labeled 2) as measured by RT-qPCR using primers for intron 1. Knockdown of RNase L or both hRRP6 and RNase L activity by targeted siRNA treatment results in loss of C9orf72 cleavage as measured by RT-qPCR using primers for exons 2-3 (n=1 iPSC cell line, 5 replicates per cell line). Figure 4D shows that knocking down XRN1 activity by targeted siRNA treatment results in abolishment of C9orf72 intron 1 degradation when co-treated with ALSFI (labeled 2). Knocking down XRN2 activity by targeted siRNA treatment does not affect C9orf72 intron 1 degradation when co-treated with RIBOTAC2 (n=1 iPSC cell line, 5 replicates per cell line). Figure 4E shows that knocking down XRN1 activity by targeted siRNA treatment results in abolishment of C9orf72 degradation when co-treated with ALSFI.Knockdown of XRN2 by targeted siRNA treatment does not affect C9orf72 degradation when co-treated with ALSFI as measured by RT-qPCR using primers for exons 2-3 (n=1 iPSC cell line, 5 replicates per cell line). [Diagram 5]Figure 5A-H show that ALSFI reduces c9ALS / FTD pathology in a BAC transgenic mouse model of r(G4C2)exp (+ / +PWR500). For all panels, vehicle indicates injection of 1% DMSO / 99% HO. *P<0.05, **P<0.001, ***P<0.0001 as determined by unpaired t-test with Welch's correction. Error bars indicate SD. Figure 5A shows that treatment with ALSFI (labeled 2) reduces C9orf72 intron 1 abundance in a + / +PWR500 mouse model of c9ALS as measured by RT-qPCR using primers specific for intron 1 (n=5 + / +PWR500 mice). FIG. 5B shows that treatment with ALSFI (labeled as 2) reduces C9orf72 exon 2-3 abundance in the + / +PWR500 mouse model of c9ALS as measured by RT-qPCR using primers specific for the exon 2-3 junction (n=5 + / +PWR500 mice). FIG. 5C shows that treatment with ALSFI (labeled as 2) does not affect C9orf72 exon 1b abundance in the + / +PWR500 mouse model of c9ALS as measured by RT-qPCR using primers specific for exon 1b (n=5 + / +PWR500 mice). FIG. 5D shows that treatment with ALSFI (labeled as 2) does not affect the C9orf72 exon 1b-exon 2 junction in the + / +PWR500 mouse model of c9ALS as measured by RT-qPCR (n=5 + / +PWR500 mice). Figure 5E shows that treatment with ALSFI (labeled as 2) reduces poly(GP) abundance in the c9 ALS+ / +PWR500 mouse model (n=5 + / +PWR500 mice) and Figure 5F shows that treatment with the ALS compound of Formula I (labeled as 2) does not affect β-actin abundance in the c9 ALS+ / +PWR500 mouse model (n=5 + / +PWR500 mice) as measured by electrochemiluminescence sandwich immunoassay.Figure 5G shows that poly(GP) is nearly undetectable in wild-type (WT;- / -PWR500) control mouse cell lines as measured by electrochemiluminescence sandwich immunoassay (n=3 WT mice), and Figure 5H shows that treatment with ALSFI (labeled 2) has no effect on β-actin abundance in the WT control mouse model as measured by electrochemiluminescence sandwich immunoassay (n=3- / -WT mice). [Figure 6]Figure 6A-F show that ALSFI (labeled 2) reduces toxic protein and RNA aggregates in + / + PWR500 mice. Vehicle indicates injection of 1% DMSO / 99% HO. *P<0.05, **P<0.001, ***P<0.0001 as determined by unpaired t-test with Welch's correction. Error bars indicate SD. Figure 6A shows immunohistochemistry (IHC) staining of the cortex of + / + PWR500 mice treated with vehicle and ALSFI (labeled 2). Arrows indicate protein aggregates. Representative images are shown (n=3 cortical slices per mouse, 5 images quantified per slide). FIG. 6B shows that treatment with ALSFI (labeled as 2) significantly reduces the number of poly(GP) aggregates per cell (n=3 + / +PWR500 mice treated with vehicle and n=3 + / +PWR500 mice treated with 2). FIG. 6C shows that treatment with ALSFI (labeled as 2) significantly reduces the number of poly(GA) aggregates per cell (n=3 + / +PWR500 mice treated with vehicle and n=3 + / +PWR500 mice treated with 2). FIG. 6C shows that treatment with ALSFI (labeled as 2) significantly reduces the number of TDP-43 aggregates per cell (n=3 + / +PWR500 mice treated with vehicle and n=3 + / +PWR500 mice treated with 2). Figure 6D shows fluorescent in situ hybridization images showing RNA foci containing r(G4C2)exp in the cortex of + / +PWR500 mice, and Figure 6F shows that treatment with ALSFI (labeled 2) significantly reduces the number of RNA foci per nucleus (n=4 vehicle-treated + / +PWR500 mice and n=4 2-treated + / +PWR500 mice). [Figure 7] FIG. 7 is a bar graph of relative melanoma differentiation associated protein 5 (MDA5) mRNA levels, an immune-related inflammatory marker that induces a viral immune response, in various doses of ALSFI compared to 2′-5′ poly(A). [Figure 8]Figures 8A-B show that ALSFI inhibits RAN translation in a transfected cell model. Figure 8A is a schematic showing that co-transfection of non-ATG-d(G4C2)66-GFP (SEQ ID NO: 45) plasmid and ATG-mCherry plasmid into HEK293T cells allows RAN translation measured based on GFP signal. mCherry signal is a measure of classical translation. Figure 8B shows that ALSFI (labeled 2) dose-dependently inhibits RAN translation in a transfected system, similar to ASO targeting r(G4C2)exp (n=3 biological replicates). **P<0.001, ***P<0.0001, ****P<0.0001 as determined by one-way ANOVA. Error bars represent SD. [Figure 9] 9A-9D show that ALSFI (labeled 2) selectively binds to r(G4C2)8 (SEQ ID NO:1) in vitro. Error bars for all panels indicate SD. FIG. 9A (left) shows binding of ALSFI to target sequence r(G4C2)8 (SEQ ID NO:1), control sequence d(G4C2)8 (SEQ ID NO:1) and r(GGCC)8 (SEQ ID NO:47) as reported by Kd measured by microscale thermophoresis. Right: Schematic of oligos used for MST binding assay. FIG. 9B is a representative binding curve of ALSFI to r(G4C2)8 (SEQ ID NO:1) (n=2 replicates each performed in technical triplicate). FIG. 9C is a representative binding curve of ALSFI to d(G4C2)8 (SEQ ID NO:1) (n=2 replicates each performed in technical triplicate). FIG. 9D shows a representative binding curve of ALSFI to r(GGCC)8 (SEQ ID NO: 47) (n=2 replicate experiments, each performed in technical triplicate). [Figure 10]Figures 10A-c show that ALSFI (labeled 2 in the figure) cleaves r(G4C2)8 (SEQ ID NO:1) in vitro. *P<0.05 as determined by one-way ANOVA. Error bars indicate SD. Figure 10 shows that treatment with ALSFI (labeled 2) cleaves 5'-end labeled (32P)r(G4C2)8 (SEQ ID NO:1) in vitro. Colored boxes indicate cleavage sites by ALSFI. Figure 10B shows quantification of the cleavage gel in Figure 10A (n=2 replicates). Figure 10C shows ALSFI-mediated cleavage sites mapped to the r(G4C2)8 (SEQ ID NO:1) hairpin structure. [Figure 11] 11A-11C show bar graphs of cell viability of ALSFI (labeled 2). Solvent shows 0.1% (v / v) DMSO. Error bars show SD. FIG. 11A shows bar graphs showing that ALSFI is not toxic in LCLs up to 1000 nM (n=1 LCL cell line, 3 replicates per cell line). FIG. 11B shows bar graphs showing that ALSFI is not toxic in c9ALS patient-derived iPSCs up to 1000 nM (n=1 C9orf72 iPSC cell line, 4 replicates per cell line). FIG. 11C shows bar graphs showing that ALSFI is not toxic in differentiated iPSNs up to 1000 nM (n=1 C9orf72 motor neuron cell line, 4 replicates per cell line). [Figure 12]Figures 12A-G are bar graphs showing the biological impact of ALSFI (labeled 2 on the graph) on healthy patients. Solvent indicates 0.1% (v / v) DMSO. Error bars indicate SD. Figure 12A shows that ALSFI does not affect C9orf72 intron 1 abundance in LCLs obtained from healthy donors as measured by RT-qPCR (n=1 healthy LCL cell line, 3 replicates per cell line). Figure 12B shows that ALSFI does not affect C9orf72 exon 1b abundance in c9ALS patient-derived iPSCs as measured by RT-qPCR (n=4 C9orf72 iPSC cell lines, 3 replicates each). Figure 12C shows that ALSFI does not affect C9orf72 intron 1 abundance in iPSCs obtained from healthy donors as measured by RT-qPCR (n=3 healthy iPSC cell lines, 3 replicates per cell line). Figure 12D shows that ALSFI does not affect C9orf72 exon 2-3 abundance in iPSCs obtained from healthy donors as measured by RT-qPCR (n=3 healthy iPSC cell lines, 3 replicates per cell line). Figure 12E shows that ALSFI does not affect C9orf72 exon 1b abundance in iPSCs obtained from healthy donors as measured by RT-qPCR (n=3 healthy iPSC cell lines, 3 replicates per cell line). Figure 12F shows that the control RNase of formula IIIA does not affect C9orf72 intron 1 abundance as measured by RT-qPCR (n=2 C9orf72 iPSC cell lines, 3 replicates each). Figure 12G shows that ALSFI affects the abundance of only one short r(G4C2)exp-containing transcript (SOCS1) compared to (G4C2)exp-targeted ASO, which affects the abundance of four short r(G4C2)exp-containing transcripts (SOCS1, XYLT1, Rab-40C and RNA BP 10) as measured by RT-qPCR using primers specific for each repeat-containing transcript (n=1 C9orf72 iPSC cell line, 3 replicates per cell line). [Figure 13]FIG. 13 is a bar graph showing relative C9orf72 intron 1 mRNA levels over time following treatment with ALSFI. [Figure 14] Figures 14A-F show graphs of iPSC treatment with ALSFI (labeled RIBOTAC2). Solvent shows 0.1% (v / v) DMSO. *P<0.05, **P<0.001, ***P<0.0001, ****P<0.0001 as determined by one-way ANOVA with multiple comparisons compared to solvent-treated samples for each transcript primer set. Error bars show SD. Figure 14A shows a bar graph showing C9orf72 intron 1:exon 2 ratio as measured by RNA-seq in c9ALS patient-derived iPSCs (n=1 C9orf72 iPSC cell line, 3 replicates per cell line). Figure 14B shows a bar graph showing RNA-seq relative read counts by treatment group in c9ALS patient-derived iPSCs. FIG. 14C is a plot showing log2 (fold change) versus gene abundance as measured by RNA-seq in c9ALS patient-derived iPSCs. Red dots indicate genes that were significantly up- or down-regulated transcriptome-wide. Blue dots represent C9orf72. FIG. 14D is a bar graph showing RNA-seq relative read counts per treatment group in healthy donor-derived iPSCs. FIG. 14E is a bar graph showing C9orf72 intron 1:exon 2 ratio as measured by RNA-seq in c9ALS patient-derived iPSCs (n=1 healthy iPSC cell line, 3 replicates per cell line). FIG. 14F is a plot showing log2 (fold change) versus gene abundance as measured by RNA-seq in healthy donor-derived iPSCs. Red dots indicate genes that were significantly up- or down-regulated transcriptome-wide. Blue dots represent C9orf72. [Figure 15]Figure 15A-B show plots and bar graphs showing that ALSFI (labeled 2) does not affect healthy C9ORF72 protein levels. Error bars indicate SD. Figure 15A shows a representative Western blot showing total C9ORF72 protein levels in c9ALS iPSCs treated with ALSFI. Figure 15B shows a bar graph representing quantification of total C9ORF72 protein levels normalized to β-actin (n=1 C9orf72 iPSC cell line, 3 replicates per cell line). [Figure 16] Figures 16A-D show bar graphs showing that ALSFI (labeled 2) has no effect on iPSCs lacking r(G4C2)exp. Solvent shows 0.1% (v / v) DMSO. Error bars show SD. Figure 16A shows bar graphs showing that ALSFI has no effect on C9orf72 exon 1b abundance in differentiated c9ALS motor neurons as measured by RT-qPCR (n=1 C9orf72 motor neuron cell line, 3 replicates each). Figure 16B shows bar graphs showing that ALSFI has no effect on C9orf72 intron 1 abundance in iPSNs differentiated from healthy donor iPSCs as measured by RT-qPCR (n=1 motor neuron cell line, 3 replicates per cell line). Figure 16C is a bar graph showing that ALSFI does not affect C9orf72 exon 2-3 abundance in iPSNs differentiated from healthy donor iPSCs as measured by RT-qPCR (n=1 motor neuron cell line, 3 replicates per cell line). Figure 16D is a bar graph showing that ALSFI does not affect C9orf72 exon 1b abundance in iPSNs differentiated from healthy donor iPSCs as measured by RT-qPCR (n=1 motor neuron cell line, 3 replicates per cell line). [Figure 17]Figures 17A-L show blots and bar graphs showing the results of targeted siRNA knockdown validation experiments. Vehicle shows 0.1% (v / v) DMSO. *P<0.05, **P<0.001, ***P<0.0001, ****P<0.0001 as determined by t-test with Welch's correction (Figures 17B, 17E, 17H, and 17K) or one-way ANOVA with multiple comparisons (Figures 17C, 17F, 17I, and 17L). Error bars show SD. Figure 17A is a western blot comparing hRRP6 protein abundance to β-actin protein abundance in vehicle-treated C9orf72 iPSCs or hRRP6-targeted siRNA. Figure 17B is a bar graph showing quantification of the western blot in Figure 17A (n=1 C9orf72 iPSC cell line, 3 replicates per cell line). Figure 17C is a bar graph showing validation of hRRP6 transcript knockdown in C9orf72 iPSCs upon hRRP6-targeting siRNA treatment as measured by RT-qPCR (n=1 C9orf72 ISPC cell line, 5 replicates per cell line). Figure 17D shows a Western blot comparing RNase L protein abundance with β-tubulin protein abundance in C9orf72 iPSCs treated with vehicle or RNase L-targeting siRNA. Figure 17E shows a bar graph showing quantification of the Western blot in Figure 17D. Figure 17F shows a bar graph showing validation of RNase L transcript knockdown in C9orf72 iPSCs upon RNase L-targeting siRNA treatment as measured by RT-qPCR. Figure 17G shows a Western blot comparing XRN1 protein abundance with Vinculin protein abundance in C9orf72 iPSCs treated with vehicle or XRN1-targeting siRNA. Figure 17H ​​is a bar graph showing quantification of the Western blot in Figure 17G. Figure 17I is a bar graph showing validation of XRN1 transcript knockdown in response to XRN1-targeted siRNA treatment in C9orf72 iPSCs as measured by RT-qPCR.Figure 17J shows a Western blot comparing XRN2 protein abundance with β-tubulin protein abundance in C9orf72 iPSCs treated with vehicle or hRRP6 targeting siRNA. Figure 17K shows a bar graph showing quantification of the Western blot in Figure 17J. Figure 17L shows a bar graph showing validation of XRN2 transcript knockdown in C9orf72 iPSCs treated with XRN2 targeting siRNA as measured by RT-qPCR. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] r(G4C2) exp Removal of r(G4C2) in an intron, but not in an open reading frame, can potentially ameliorate the defect in the entire c9ALS / FTD molecule, which is an advantageous advantage over targeting a specific c9ALS / FTD pathway. exp The presence of ensures the advantage.

[0017] To enable such an approach, the use of structure-activity relationships (SAR), i.e., biophysical and structural analyses, has led to the identification of r(G4C2) exp We have developed high affinity compounds of formula II, i.e. pyridocarbazole compounds, for selectively recognizing r(G4C2) exp and downstream disease-associated pathology thereof.

[0018] r(G4C2) exp Rational design of monomeric compounds that bind to By applying the ReFrame library along with SAR chemical modification combined with HEK293T cell screening, r(G4C2) of Formula II was obtained. exp This led to the selection of a binding compound (labeled compound 1 in Figure 1A). Compound of formula II (labeled 1 in the figure) had a K d DeR(G4C2) expand reduces the abundance of poly(GP) (the most soluble DPR) and nuclear focus formation in patient-derived cell lines. Additionally, the r(G4C2) exp Binding of C9orf72 to the hairpin structure leads to endogenous degradation of C9orf72 intron 1, thus eliminating the disease-causing RNA via the natural RNA quality control pathway.

[0019] Extending the availability of the compound of formula II in cells and exp To allow for the efficient degradation of and / or reduction of its repeat translation, the compound of formula II was converted into a ribonuclease-targeted chimera, i.e., the ALS compound of formula I (labeled 2; FIG. 1B). This ALS compound of formula I consists of the compound of formula II linked to a ribonuclease L (RNase L) recruiting moiety of formula IIIA via a short polyethylene glycol (PEG) linker of formula IV (see also FIG. 1). RNase L is an endogenous ribonuclease that is ubiquitously present in small amounts as an inactive monomer in cells. 23,24 During the immune response to viral infection, cells synthesize 2'-5' polyadenylic acid (polyA), an endogenous ligand for RNase L, to dimerize and activate the ribonuclease, thus inducing cleavage of the invading viral RNA. 23,25 However, in the case of RIBOTAC-type compounds, e.g., compounds having an RNase L recruitment moiety of formula IIIA, the RNase L recruitment moiety of formula IIIA activates RNase L locally in close proximity to disease-causing RNA transcripts, thus resulting in selective cleavage of the target RNA without inducing a widespread immune response (Figure 1C and Figure 7). 26~29 .

[0020] ALS compounds of formula I inhibit RNA translation in transfected cell models The ALS compound of formula I was tested in an RNase L translation assay in HEK293T cells to assess whether the addition of the RNase L recruitment moiety of formula IIIA affected the ability of the small molecule to reduce RNase translation (FIG. 8A). The ALS compound of formula I had an IC of about 500 nM. 50 RIBOTAC dose-dependently reduced GFP signal (Figure 8B), indicating that the added RNase L recruitment moiety of Formula IIIA does not interfere with the ability of the ALS compound of Formula I to reduce RNase L translation. The ALS compound of Formula I has no effect on mCherry signal, indicating that classical translation is not affected by RIBOTAC.

[0021] Affinity and Selectivity of ALS Compounds of Formula I The in vitro affinity and selectivity of the ALS compounds of formula I were then measured by microscale thermophoresis (MST). Three nucleic acid constructs were used to assess small molecule binding. The ALS compounds of formula I have d = 3.30 ± 1.91 μM for r(G4C2)8 (SEQ ID NO: 1), i.e. r(G4C2) exp (FIGS. 9A-9B). No saturation binding was observed to the base pair control constructs, r(GGCC)8 (SEQ ID NO:47) or d(G4C2)8 (SEQ ID NO:1), at concentrations up to 20 μM, indicating that the ALS compound of Formula I is selective for the structured hairpin of r(G4C2)8 (SEQ ID NO:1), which is not present in the base pair control and DNA constructs (FIGS. 9A, 9C, and 9D).

[0022] r(G4C2) with ALS compounds of formula I exp In vitro validation of RNase L-mediated cleavage of The ability of ALS compounds of Formula I to cleave r(G4C2)8 (SEQ ID NO:1) in vitro via RNase L recruitment was evaluated. 32P-radiolabeled r(G4C2)8 (SEQ ID NO:1) was treated with a constant concentration of RNase L and increasing concentrations of the ALS compound of formula I, and the resulting fragments were analyzed by polyacrylamide gel electrophoresis. Significant cleavage of r(G4C2)8 (SEQ ID NO:1) was observed at doses of 10 μM and 20 μM of the ALS compound of formula I, indicating that RNase L is recruited by the ALS compound of formula I to cleave the target RNA in vitro. The cleavage sites were mapped to the GC base pairs preceding each 1×1GG internal loop in the hairpin structure of r(G4C2)8 (SEQ ID NO:1) ( FIG. 10 ).

[0023] Cytotoxicity of ALS Compounds of Formula I To evaluate the ability of the ALS compound of formula I to rescue c9ALS / FTD-related pathology in cells, we utilized three cell lines from both c9ALS / FTD patients and healthy donors: 1) lymphoblastoid cell lines (LCLs), 2) induced pluripotent stem cells (iPSCs), and 3) motor neurons differentiated from iPSCs (iPSNs). In all three cell lines, the ALS compound of formula I showed no significant toxicity at doses up to 1 μM (Figure 11).

[0024] ALS compounds of Formula I exhibited the following properties in patient-derived cell models: exp Bind to The ALS compound of formula I was first tested in c9ALS / FTD patient-derived LCLs to test its ability to reduce c9ALS / FTD-associated cellular pathology. At a dose of 500 nM, the ALS compound of formula I reduced RAN translation by approximately 50%, as measured by poly(GP) abundance using an electrochemiluminescence sandwich immunoassay as a readout (Figures 2A-B). Real-time quantitative polymerase chain reaction (RT-qPCR) was further used to measure the abundance of three C9orf72 transcript isoforms: 1) r(G4C2) exp Introns 1 and 2 of C9orf72 containing r(G4C2) expr(G4C2) exp Primers specific for either the r(G4C2) site or the r(G4C2) site were designed (Figure 2C). Using primers specific for intron 1 of C9orf72 revealed a 50% reduction in intron 1 abundance upon treatment with 500 nM of the ALS compound of formula I (Figure 2D). However, in lymphoblastoid cells obtained from healthy donors, treatment with the ALS compound of formula I did not reduce C9orf72 intron 1 levels as measured by RT-qPCR (Figure 12A). The presence of the r(G4C2) site in intron 1 of C9orf72 revealed a 50% reduction in intron 1 abundance upon treatment with 500 nM of the ALS compound of formula I (Figure 2C). exp As expected in cells that do not have poly(GP), poly(GP) was undetectable by our electrochemiluminescence sandwich immunoassay in cells from healthy donors.

[0025] A competition assay was performed between the compound of formula II and the ALS compound of formula I to determine the r(G4C2) exp We confirmed target binding with exon 2-exon 3. However, because treatment with the compound of formula II also caused a decrease in C9orf72 intron 1 levels, RT-qPCR was completed using primers spanning the exon 2-exon 3 junction of C9orf72 (as a measure of the complete C9orf72 transcript, not just the intron containing the RNA repeat). Cells were treated with increasing doses of the compound of formula II and a fixed concentration of the ALS compound of formula I (100 nM). As expected, increasing concentrations of the compound of formula II competed with the ALS compound of formula I for binding of the 1x1GG internal loop, thus reducing the cleavage observed by RT-qPCR when exon 2-3 primers were used (Figure 2E). These data demonstrate that both the compound of formula II and the ALS compound of formula I inhibited r(G4C2) in cells. exp Targeting of the repeat is confirmed.

[0026] A more advanced cellular model of c9ALS / FTD (patient-derived iPSCs) was also examined. The effect of the ALS compound of formula I on poly(GP) and C9orf72 intron 1 abundance was measured. The ALS compound of formula I reduced poly(GP) abundance by approximately 50% at 500 nM, and remained reduced by approximately 20% 48 hours after treatment (Figure 3D). Interestingly, 48 hours after treatment with the compound of formula II, poly(GP) abundance was restored to that of the solvent-treated sample (Figure 3). C9orf72 intron 1 abundance was also reduced by approximately 50% upon treatment with 500 nM of the ALS compound of formula I (labeled 2, Figure 3B). C9orf72 exon 2-3 abundance was only reduced by approximately 30% as measured by RT-qPCR, indicating that the exon 2-3 junction is a r(G4C2) containing exon 1a isoform. exp Consistent with the fact that exon 1b is present in both the healthy and non-repeat containing alternatively spliced ​​exon 1b isoforms, exon 2-3 primers therefore measure abundance of both healthy and disease-causing C9orf72 transcripts (Figure 3C). Furthermore, primers specific for the exon 1b isoform, an exon present only in properly spliced ​​healthy C9orf72 transcripts, showed no reduction upon treatment with the ALS compound of formula I as measured by RT-qPCR, further confirming the selectivity of the ALS compound of formula I for the disease-causing transcript (Figure 12B). iPSCs derived from healthy donors showed no reduction in C9orf72 intron 1, exon 2-3 or exon 1b levels as measured by RT-qPCR with appropriate primers (Figures 12C-E). Healthy cells expressed structured r(G4C2) expThis is expected, since the ALS compound of formula I, which possesses the ribonuclease recruitment module of formula IIIA, allows complete cleavage of the disease-associated isoform as assessed by exon 2-3 abundance. This cleavage resulted in a long-term bioactivity, as measured by washout experiments, in which upon removal of the compound from the cell medium, C9orf72 intron 1 abundance required 48 hours to return to pre-compound intervention levels (Figure 3).

[0027] Additionally, a less efficient RIBOTAC (compound 3, FIG. 1B) was synthesized of the compound of formula II by use of a conjugate with a significantly less effective stereoisomer of the RNase L recruitment module of formula IIIA (compound 3, FIG. 1B) in which R″ is a bond and R′ is H. Thus, compound 3 lacks the ability to recruit RNase L and cleave the complete C9orf72 transcript, but still acts via a simple conjugation mechanism of action like the compound of formula II (FIG. 6F).

[0028] Furthermore, by using RT-qPCR to measure the abundance of eight additional transcripts containing shorter, non-pathogenic r(G4C2) (SEQ ID NO: 48) repeats (repeat lengths of 2-4, i.e., do not form RNA hairpin structures), only one transcript, SOCS1, was significantly decreased upon treatment with the ALS compound of formula I, and r(G4C2) exp Treatment with the targeted ASO was found to significantly reduce the levels of four of these transcripts (Figure 12G). However, when RNA sequencing (RNA-seq) was performed, SOCS1 was not found to be significantly downregulated (Figure 14C). These data suggest that the ALS compound of Formula I significantly downregulated r(G4C2) exp This further supports the fact that it recognizes the structure but not the primary sequence of this RNA repeat, making this small molecule more selective than ASO for targeting this RNA repeat.

[0029] Furthermore, RNA-seq analysis of c9ALS / FTD patient-derived iPSCs revealed that treatment with the ALS compound of formula I (50 nM) significantly reduced the intron 1:exon 2 ratio but had no effect on total C9orf72 read counts and minimal off-target transcriptome-wide (Figures 14A-C). In iPSCs obtained from healthy donors, the ALS compound of formula I induced no effect on the intron 1:exon 2 ratio or C9orf72 read counts and had minimal off-target effects transcriptome-wide (Figures 14D-F).

[0030] The effect of the ALS compound of Formula I on total C9ORF72 protein levels in c9ALS / FTD patient-derived iPSCs was examined. Treatment with the ALS compound of Formula I increased C9ORF72 protein levels by r(G4C2) exp As expected, given that translation occurs from a properly spliced ​​C9orf72 transcript that does not contain r(G4C2), there was no effect on healthy C9orf72 protein levels (Figures 15A-B). exp Reducing the abundance of transcripts containing C9orf72 does not affect the levels of healthy C9orf72 transcripts that are present.

[0031] c9ALS / FTD iPSCs were differentiated into spinal cord neurons (iPSNs) following a detailed 32-day differentiation protocol described previously. RNA and protein were harvested from iPSNs at the end of day 32 and analyzed as described above. When treated with ALS compound of formula I for 17 days (days 15-32 of differentiation), poly(GP) abundance in c9ALS / FTD iPSNs was reduced by approximately 60% at 500 nM (Figure 3E). Further RT-qPCR analysis showed a dose-dependent reduction in C9orf72 intron 1 levels (reduced by approximately 50% at 500 nM ALS compound of formula I; Figure 3F) and exon 2-3 abundance (reduced by approximately 40% at 500 nM ALS compound of formula I; Figure 3G), while exon 1b transcript abundance was unaffected (Figure 16A). No effects on intron 1, exon 2-3 or intron 1b levels were observed in healthy iPSNs upon compound treatment (Figures 16B-D). These data indicate that the ALS compounds of Formula I have biologically relevant activity in a complex cellular model of c9ALS / FTD.

[0032] ALS compounds of Formula I function via a unique mechanism of action to reduce C9orf72 transcript abundance Previous studies with the parent RNA binding agent, i.e., the compound of formula II, have demonstrated that this small molecule has the unique ability to induce C9orf72 intron 1 degradation without degrading the entire transcript, i.e., upon binding of the compound of formula II, r(G4C2) expIt was demonstrated that the intron bearing the α-terminal β ... Treatment with 20 nM hRRP6-targeting siRNA and 50 nM ALS compound of formula I shows abolishment of intron 1 degradation but no effect on exon 2-3 cleavage, indicating that hRRP6 is only acting to degrade the intron and not the entire C9orf72 transcript (Figure 4B-4C). Furthermore, treatment with 20 nM RNase L-targeting siRNA and 50 nM ALS compound of formula I shows abolishment of both intron 1 and exon 2-3 degradation, indicating that the C9orf72 transcript is no longer cleaved (Figure 4B-4C). Both RNase L and hRRP6 were then knocked down by siRNA treatment, resulting in degradation of the transcript comparable to RNase L knockdown alone (Figure 4B-4C). These data therefore suggest that the ALS compound of formula I RIBOTAC inhibits r(G4C2) cleavage, which are separated by their subcellular location. expWe show that C9orf72 acts via two distinct mechanisms to degrade intron 1 transcripts: intron 1 degradation is governed by the nuclear exosome, and RNase L-mediated degradation is governed in the cytoplasm, consistent with the cellular localization of RNase L.

[0033] Interestingly, the degradation mechanism of C9orf72 appears rather complex when exoribonucleases XRN1 and XRN2 are also considered. These proteins are involved in 5'-3' endogenous RNA degradation and differ only in their subcellular localization, where XRN1 is in the cytoplasm and XRN2 is in the cell nucleus (Figure 17G-L). Treatment with 20 nM XRN1-targeting siRNA and 50 nM ALS compound of formula I shows abolishment of intron 1 degradation and C9orf72 cleavage, whereas treatment with 20 nM XRN2-targeting siRNA and 50 nM ALS compound of formula I has no effect on either (Figure 4D and Figure 4E). These data are consistent with RNase L-mediated cleavage of C9orf72 in the cytoplasm and its subsequent complete degradation by XRN1. These data further highlight the importance of subcellular localization in the ALS compound of formula I-mediated C9orf72 degradation mechanism of action.

[0034] ALS Compounds of Formula I Ameliorate c9ALS / FTD Pathology In Vivo Given the success of the ALS compound of formula I, RIBOTAC, in patient-derived cell models, we next sought to test the compound's ability to reduce c9ALS / FTD pathology in vivo. A C9orf72 BAC transgenic (C9BAC) mouse model expressing approximately 500 G4C2 repeats (referred to as + / +PWR500 mice) was utilized as the model system. Following treatment with a single intracerebroventricular injection (ICV) of 10 mg / kg of the ALS compound of formula I and a subsequent 3-week incubation period, mice were sacrificed and brain tissue was collected for downstream analysis. RT-qPCR of total RNA collected from total brain tissue revealed that C9orf72 intron 1 abundance was reduced by approximately 25% and exon 2-3 abundance was reduced by approximately 20% in + / +PWR500 mice (Figures 5A-B). Exon 1b abundance and exon 1b-exon 2 spanning primers (represented by C9orf72 abundance in humans) did not change after the course of treatment, indicating that exon 1b is r(G4C2) exp This is consistent with the fact that this is only present in wild-type C9orf72 transcripts lacking the .alpha.-dimer (Figure 5C-D).

[0035] Proteins were also collected from the brains of these mice and analyzed for poly(GP) abundance. In + / +PWR500 mice, poly(GP) was reduced by approximately 40%, whereas β-actin abundance, also used here as a housekeeping protein, was unaffected by treatment with the ALS compound of formula I (Figure 5E-F). Poly(GP) was barely detectable in - / -PWR500 (WT) mice, whereas β-actin was readily detectable and showed no reduction upon treatment with the ALS compound of formula I (Figure 5G-H). Immunohistochemistry (IHC) analysis of cortical slices from + / +PWR500 mice also showed that upon treatment with the ALS compound of formula I, inclusion of poly(GP), poly(GA) [another DPR produced from RAN translation] and TDP-43 [a well-established biomarker for c9ALS / FTD disease progression] was significantly decreased, further indicating that c9ALS / FTD pathology can be alleviated by the ALS compound of formula I (Figures 6A-D).

[0036] C9orf72r(G4C2) exp Using fluorescence in situ hybridization (FISH) studies with a TYE563-labeled oligo complementary to the sense strand of r(G4C2) exp The effect of the ALS compound of Formula I on nuclear foci resulting from sequestration of hnRNP H on c9ALS / FTD, another hallmark of c9ALS / FTD, was examined. Treatment with the ALS compound of Formula I reduced the presence of r(G4C2) in the nuclei of cortical neurons in + / +PWR500 mice treated with the ALS compound of Formula I compared to vehicle-treated + / +PWR500 mice. exp r(G4C2) , indicating that the ALS compound of Formula I alleviates c9ALS / FTD nuclear foci in vivo (Figure 6E-F). Thus, the ALS compound of Formula I reduced C9orf72 intron 1 transcript abundance, reduced poly(GP) abundance, and reduced r(G4C2) foci. exp It destroys nuclear foci containing , reduces toxin inclusion in vivo, and does not cause toxicity to mice.

[0037] Mechanism of action and medical treatment In a particular embodiment, the present invention relates to aberrant repeat RNA r(G4C2) associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). exp These abnormal RNA repeats are present in cell lines and patients with ALS and FTD. ALS compounds can reduce the translation of abnormal repeat RNA by binding to the repeats or inducing their cleavage. The ALS compounds of formula I (hereinafter "compounds" or "compounds of the invention") as embodiments of the invention for use in the methods disclosed herein bind to the RNA entities identified above and improve and / or inhibit their translation into disease-causing dipeptide repeat proteins as well as foci formation and nuclear transport.

[0038] Embodiments of the compounds and pharmaceutical compositions thereof applied in the methods of the present invention can function as "inhibitors", suppressors and / or modulators of the RNA entities identified above, meaning that they can block, suppress or reduce translation of the RNA entities by simply binding to or facilitating their cleavage.

[0039] Compounds useful for the methods and pharmaceutical compositions of the present invention function as therapeutic agents in that they can prevent, ameliorate, modulate, and / or affect a disease or condition. Characterization of such a compound as a therapeutic agent means that in a statistical sample, the compound reduces the occurrence or delays the onset of a disease or condition in treated samples relative to untreated control samples, or reduces the severity of one or more symptoms of a disease or condition relative to untreated control samples.

[0040] The ability to prevent, ameliorate, modulate, and / or affect conditions such as localized recurrences (e.g., pain) of the disease known as ALS / FTD disease may be achieved according to embodiments of the methods of the invention, including administration of a composition as described above that reduces or delays or inhibits or prevents deleterious pathology in an ALS / FTD subject relative to a subject to which the composition is not administered.

[0041] The compounds of the present invention, as well as salts and solvates thereof, are capable of binding to the repeat RNA [G4C2 exp The compounds may also be used alone or in combination with other therapeutic agents for the treatment of diseases or conditions associated with the inflammatory bowel disease (AIDS) or inflammatory bowel disease (IGF).

[0042] The compounds of the present invention and pharmaceutical compositions thereof can function prophylactically and / or therapeutically, and include administration of one or more of the subject compositions to a host / patient, where the treatment is prophylactic (i.e., it protects the host from developing the undesirable condition) when administered prior to the clinical manifestation of an undesirable condition (e.g., a disease or other undesirable condition in the host animal / patient), and where the treatment is therapeutic (i.e., aimed at reducing, ameliorating or stabilizing an existing undesirable condition or its side effects) when administered after the manifestation of an undesirable condition.

[0043] The compounds of the present invention and their pharmaceutical compositions are capable of prophylactic and / or therapeutic treatment. When the compounds or pharmaceutical compositions are administered before the clinical manifestation of an undesirable condition (e.g., a disease or other undesirable condition in a host animal), the treatment is preventative (i.e., they protect the host from developing the undesirable condition), and when they are administered after the manifestation of an undesirable condition, the treatment is therapeutic (i.e., they aim to reduce, ameliorate or stabilize an existing undesirable condition or its side effects). As used herein, the term "treat" or "treatment" includes ameliorating, reducing or arresting symptoms, clinical signs and underlying pathology of a condition in a manner that improves or stabilizes the subject's condition.

[0044] The compounds of the present invention and pharmaceutical compositions thereof can be administered in a "therapeutically effective amount" in relation to the subject treatment methods. A therapeutically effective amount is an amount of one or more of the present compounds in a pharmaceutical composition that, when administered (to a mammal, preferably a human) as part of a desired dosing regimen, alleviates symptoms, ameliorates a condition, or delays the onset of a disease state according to clinically accepted criteria for the disease or condition being treated, e.g., with a reasonable benefit / risk ratio applicable to any medical treatment.

[0045] Administration The compounds of the present invention and their pharmaceutical compositions prepared as described herein can be administered according to the methods described herein by using various forms of administration depending on the disease to be treated and the age, condition and weight of the patient as is well known in the art. Administration is ultimately given under the guidance and prescription of the attending physician whose wisdom, experience and knowledge control the treatment of the patient, as is consistent with and recommended and required by the medical authorities and government registration offices for pharmaceuticals.

[0046] For example, when the compounds are administered orally, they may be formulated as tablets, capsules, granules, powders or syrups, or for parenteral administration, they may be formulated as injections (intravenous, intramuscular, subcutaneous or intrathecal), drops or suppositories. For application via the ocular or other similar mucosal routes, they may be formulated as eye drops or ointments.

[0047] These preparations for administration by oral or mucosal routes can be prepared by conventional means and, if desired, the active ingredient may be mixed with any conventional additives or excipients, such as binders, disintegrants, lubricants, flavorings, solubilizers, suspending aids, emulsifiers, coating agents, cyclodextrins and / or buffers. The dosage may generally vary depending on the condition, age and weight of the patient, the sex of the patient, the nature and severity of the disease to be treated or prevented, the route of administration and the form of the drug, but a daily dosage of 0.0001-2000 mg, preferably 0.001-1000 mg, more preferably 0.001-500 mg, particularly preferably 0.001-250 mg, most preferably 0.001-150 mg of the compound is recommended for adult human patients, which may be administered in a single dose or in divided doses. Alternatively, the daily dose may be administered according to body weight, such as from 1 nanogram / kg (ng / kg) to 200 mg / kg, preferably from 10 ng / kg to 100 mg / kg, more preferably from 10 ng / kg to 10 mg / kg, and most preferably from 10 ng / kg to 1 mg / kg. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

[0048] The exact administration time and / or amount of the compound and / or pharmaceutical composition that will produce the most effective results in terms of efficacy of treatment in a given patient will depend on the activity, pharmacokinetics and bioavailability of the particular compound, the physiological condition of the patient (including age, sex, type and stage of disease, general physical condition, responsiveness to a given dosage and type of medication), route of administration, etc. However, the above guidelines can be used as a basis for fine-tuning the treatment, e.g., for determining optimal administration time and / or amount, which requires only routine experimentation consisting of subject monitoring and adjustment of dosage and / or timing.

[0049] The phrase "pharmacologically acceptable" is used herein to refer to those excipients, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0050] Pharmaceutical Compositions Incorporating ALS Compounds of Formula I The pharmaceutical composition of the present invention incorporates the ALS compound of formula I and a pharma- ceutical acceptable carrier that is useful for the method of the present invention.The composition and its pharmaceutical composition can be administered orally, topically, parenterally, by inhalation or spray or rectally in a dosage unit formulation.The term parenteral is described in detail below.The nature of the pharmaceutical carrier and the dosage of these ALS compounds depend on the selected administration route, the effective dosage for such route and the wisdom and experience of the attending physician.

[0051] A "pharmacologically acceptable carrier" is a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can function as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch, potato starch, and substituted or unsubstituted (3-cyclodextrins; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and the like. (10) oils, such as koshi oil and soybean oil; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar, (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) phosphate buffers, and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0052] Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweeteners, flavorings and fragrances, preservatives and antioxidants may also be present in the composition. Examples of pharmaceutically acceptable antioxidants include (1) water-soluble antioxidants such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite and sodium sulfite, (2) oil-soluble antioxidants such as ascorbyl palmitate, butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), lecithin, propyl gallate and α-tocopherol, and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid and phosphoric acid.

[0053] Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or solutions or suspensions in aqueous or non-aqueous liquids, or oil-in-water or water-in-oil liquid emulsions, or elixirs or syrups, or pastilles (using an inert matrix such as gelatin and glycerin or sucrose and acacia) and / or mouthwashes, each containing a predetermined amount of a compound of the invention as an active ingredient. The compositions may also be administered as a bolus, electuary, or paste.

[0054] In solid dosage forms for oral administration (such as capsules, tablets, pills, dragees, powders and granules), the compounds of the invention may be administered in the form of a mixture of sodium citrate or dicalcium phosphate and / or (1) fillers or extenders, such as starch, cyclodextrin, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and / or acacia; (3) Moisturizers such as glycerin, (4) Disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) Dissolution retarders such as paraffin, (6) Absorption enhancers such as quaternary ammonium compounds; (7) humectants, such as acetyl alcohol and glyceryl monostearate; (8) Absorbents such as kaolin and bentonite clays; (9) Lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; (10) Coloring agents The pharmaceutical composition may be mixed with one or more pharma- ceutically acceptable carriers, such as any of the following: For capsules, tablets, and pills, the pharmaceutical composition may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules, using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols.

[0055] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of one or more powdered inhibitors moistened with an inert liquid diluent.

[0056] Tablets and other solid dosage forms such as dragees, capsules, pills and granules may be optionally scored or prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may also be formulated to provide sustained or controlled release of the active ingredient, for example, by using hydroxypropylmethylcellulose, other polymer matrices, liposomes and / or microspheres therein in various proportions to provide the desired release profile. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents, and may be of a composition that releases one or more active ingredients only, or preferentially, optionally delayed, in a certain part of the gastrointestinal tract.

[0057] Examples of embedding compositions which can be used include polymeric substances and waxes.The compounds of the invention can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0058] The liquid dosage form for oral administration includes pharma- ceutically acceptable emulsion, microemulsion, solution, suspension, syrup and elixir.In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerin, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.

[0059] Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0060] Suspensions may contain, in addition to one or more active inhibitors, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0061] Formulations for rectal or vaginal administration may be prepared by mixing one or more inhibitors with one or more suitable non-irritating excipients or carriers, such as, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and may be provided as a suppository which is solid at room temperature but liquid at body temperature and therefore will melt in the rectal or vaginal cavity releasing the active agent(s).

[0062] Formulations suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or sprays containing such carriers as are known in the art to be appropriate.

[0063] Dosage forms for topical or transdermal administration of one or more inhibitors include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active ingredient may be mixed under sterile conditions with a pharma- ceutically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0064] The ointments, pastes, creams and gels may contain, in addition to the compounds of the present invention, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide or mixtures thereof.

[0065] Powders and sprays may contain, in addition to the compounds of the invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0066] The compounds useful for the application of the method of the present invention can alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal formulation or solid particles containing the composition. A non-aqueous (e.g. fluorocarbon propellant) suspension can be used. Sonic nebulizers are preferred because they minimize the exposure of the agent to shear forces that can cause the compound to decompose.

[0067] Usually, aqueous aerosol is prepared by formulating the aqueous solution or suspension of the compound of the present invention with conventional pharma- ceutically acceptable carriers and stabilizers.Carriers and stabilizers vary according to the requirements of specific compositions, but typically include non-ionic surfactants (Tween, Pluronic, sorbitan esters, lecithin, Cremophor), pharma-ceutically acceptable cosolvents such as polyethylene glycol, innocuous proteins such as serum albumin, amino acids such as oleic acid, glycine, buffers, salts, sugars or sugar alcohols.Aerosols are generally prepared from isotonic solutions.

[0068] Transdermal patches have the added advantage of providing controlled delivery of the compounds of the present invention to the body. Such dosage forms can be prepared by dissolving or dispersing the drug in a suitable solvent. Absorption enhancers can also be used to increase the flux of one or more inhibitors across the skin. Such flux rate can be controlled by providing a rate-controlling membrane or by dispersing one or more inhibitors in a polymer matrix or gel.

[0069] The pharmaceutical composition of the present invention suitable for parenteral administration comprises one or more compounds of the present invention in combination with one or more pharma- ceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted into sterile injection solutions or dispersions immediately before being made isotonic with the blood or suspension or thickening agent of the intended recipient.Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical composition of the present invention include water, ethanol, polyols (such as glycerin, propylene glycol and polyethylene glycol) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0070] These compositions may also contain auxiliary agents such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of microbial action may be ensured by including various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol and sorbic acid. It may be desirable to include isotonic agents such as sugars and sodium chloride in the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0071] In some cases, in order to prolong the effect of a compound useful for practicing the methods of the present invention, it is desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. For example, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0072] Injectable depot forms are prepared by forming microencapsule matrices of one or more inhibitors in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug:polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0073] The pharmaceutical compositions may be administered orally, parenterally, topically or rectally. They are, of course, administered in a form suitable for each administration route. For example, they are administered in tablet or capsule form, injection, inhalant, eye lotion, ointment, suppository, infusion or lotion or ointment for topical administration, and suppository for rectal administration. Oral administration is preferred.

[0074] The phrases "parenteral administration" and "administering parenterally" as used herein refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0075] The pharmaceutical compositions of the present invention are "systemically administered" and "peripherally administered", which means administration of a ligand, drug or other material other than directly to the central nervous system, e.g., subcutaneous administration, such that it enters the patient's system and is therefore subject to metabolic and other similar processes.

[0076] The one or more compounds useful for application in the methods of the present invention may be administered to humans and other animals for treatment by any suitable route of administration, including orally, nasally, e.g., by sprays, rectally, vaginally, parenterally, intracisternally, and topically (including buccal and sublingually), such as by powders, ointments, or eye drops.

[0077] Regardless of the route of administration selected, one or more compounds useful for application in the methods of the present invention, which may be used in suitable hydrated form and / or in the pharmaceutical compositions of the present invention, are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0078] The actual dosage levels of one or more compounds useful for the application of the methods of the present invention in the pharmaceutical compositions of the present invention may be varied to provide an effective amount of active ingredient to achieve the desired therapeutic response for a particular patient, composition and mode of administration without being toxic to the patient.

[0079] The concentrations of compounds useful for application of the methods of the present invention in pharma- ceutically acceptable mixtures will vary depending on several factors, including the dosage of the compound administered, the pharmacokinetic properties of the compound or compounds used, and the route of administration.

[0080] In general, compositions useful for application of the methods of the invention may be provided as aqueous solutions containing about 0.1-10% w / v of a compound disclosed herein, among other substances, for parenteral administration. Typical dosage ranges are provided above and may be preferably about 0.001 to about 500 mg / kg of body weight per day, administered in 1-4 divided doses. Each divided dose may contain the same or different compounds of the invention. The dosage is an effective amount depending on several factors, including the overall health of the patient, as well as the formulation and route of administration of the compound(s) selected. EXAMPLES

[0081] material and method Quantification and statistical analysis All quantification and statistical analyses (completed in GraphPad Prism version 8) were completed as described in the figure legends and methods. Briefly, statistical analysis for all experiments completed in c9ALS / FTD patient-derived cells consisted of repeated measures of the same patient cell line using repeated measures one-way or two-way ANOVA. Multiple samples were compared using Tukey's multiple comparison test as indicated in the figure legends. For studies completed in vitro, i.e., in HEK293T cells, statistical significance was determined by using one-way ANOVA or t-test as indicated. For all panels where statistical significance is indicated, *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Bar graphs show individual data points and are reported as mean ± SD. All compound-treated samples were normalized to vehicle unless otherwise noted. DMSO concentrations in vehicle-treated samples were always 0.1% or less.

[0082] Biochemical and biophysical methods Summary. RNA and 5'-biotinylated oligonucleotides were purchased from Dharmacon (GE Healthcare). All oligos were deprotected as outlined in the manufacturer's protocol and subsequently desalted with PD-10 columns (GE Healthcare). Oligonucleotide concentrations were determined by UV / VIS spectroscopy using a Beckman Coulter DU 800 spectrophotometer. Absorbance was measured at 260 nm and 90 °C (extinction coefficients for RNA were provided by the vendor). The structures and sequences of the RNA hairpins reported in this study are listed in Table 1. DNA oligonucleotides were obtained from Integrated DNA Technologies (IDT) and standard desalting was provided by the manufacturer. These oligos were used without further purification. The sequences of the DNA oligonucleotides (including primers) used in this study are listed in Table 2.

[0083] In vitro methods Affinity measurements by Microscale Thermophoresis (MST). Affinity measurements were performed by MST using a Monolith NT.115 system (NanoTemper Technologies) with 5'-Cy5-labeled r(G4C2)8 (SEQ ID NO:1), 5'-Cy5-labeled d(G4C2)8 (SEQ ID NO:1), and 5'-Cy5-labeled base pair control r(G2C2)4GAAA(G2C2)4 (SEQ ID NO:49). All oligos were deprotected according to the manufacturer's recommended protocol. Samples were prepared as previously described. 30 Briefly, RNA or DNA (5 nM) was folded in 1x MST buffer (8 mM Na2HPO4, 185 mM NaCl, 1 mM EDTA) by heating at 95 °C for 5 min and slowly cooling to room temperature. Tween 20 was then added to a final concentration of 0.05% (v / v). Serial dilutions of compounds were then performed in 1x MST buffer containing 5 nM of folded nucleic acid to obtain the desired compound concentrations. Samples were incubated at room temperature for 90 min and then loaded into premium capillaries (NanoTemper Technologies). The following parameters were used on the Monolith NT.115 system: 10% LED, 20-80% MST power, laser on time = 30 s, laser off time = 5 s. Fluorescence was detected using an excitation wavelength of 605-645 nm and an emission wavelength of 680-685 nm. The data obtained were analyzed by thermophoretic analysis and fitted using a quadratic binding equation in MST analysis software (NanoTemper Technologies). Dissociation constants were determined using Equation 1. The reported K d Values ​​are the average of three independent experiments.

number

[0084] In vitro RIBOTAC cleavage mapping: gel analysis. As previously described, r(G4C2)8 (SEQ ID NO: 1) (r(G4C2) exp The 5' end of the model 32Radiolabeled with P and purified on a denaturing polyacrylamide gel (15%) 31,32 After purification, the labeled RNA (25 nM) was folded in 1x RNase L buffer (25 mM Tris-HCl (pH 7.4) and 100 mM NaCl) at 95°C for 5 min. The folded RNA was cooled to room temperature and 2-mercaptoethanol (7 mM final concentration), ATP (50 μM final concentration) and MgCl2 (10 mM final concentration) were added to the solution. Compound dilutions were then made in the folded RNA solution and incubated at room temperature for 15 min. After incubation, RNase L was added to a final concentration of 50 nM. The samples were incubated overnight at 37°C. The cleaved fragments were then separated on a denaturing 15% polyacrylamide gel, imaged by autoradiography (Typhoon FLA 9500) and quantified using QuantityOne software (BioRad). All experiments were performed in duplicate.

[0085] cell methods Cell culture. HEK293T cells (CRL-3216) were obtained from the American Type Culture Collection (ATCC): CRL-3216 (female, fetal). HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Corning) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich), 1% penicillin-streptomycin (PS; Corning) and 1% glutagro supplement (Corning) at 37°C and 5% CO2.

[0086] Patient-derived lymphoblastoid cell lines (LCLs) were obtained from the Coriell Institute: ND11583 (male, 59 years old, with GGGGCC expansion), ND12438 (male, 65 years old, with GGGGCC expansion), ND09492 (male, 52 years old, with GGGGCC expansion) and GM07491 (male, 17 years old, healthy). LCLs were maintained at 37°C and 5% CO2 in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% (v / v) FBS, 1% (v / v) penicillin-streptomycin solution (Life Technologies) and 1% (v / v) Glutagro (Life Technologies).

[0087] ALS and healthy patient-derived induced pluripotent stem cell (iPSC) lines were obtained from the Laboratory for Neurodegenerative Research, Johns Hopkins University School of Medicine: CS0BUU (female, 63 years old, with GGGGCC expansion); CS7VCZ (male, 64 years old, with GGGGCC expansion), CS0NKC (female, 60 years old, with GGGGCC expansion); CS2YNL (male, 60 years old, with GGGGCC expansion); CS8PAA (female, 58 years old, healthy), CS9XH7 (male, 53 years old, healthy), EDi044-A (female, 80 years old, healthy) and CS1ATZ (male, 60 years old, healthy). iPSCs were maintained in mTeSR™1 feeder-free medium (basal medium) (STEMCELL Technologies; catalog number 85850) in Matrigel (Corning, catalog number 356234) coated plates according to STEMCELL's protocol. Compound treatment of iPSCs was performed in basal medium in Matrigel-coated 6-well plates for 4 days. On days 1 and 3, this medium was removed and fresh medium containing compound was added to each well. The final concentration of DMSO in all samples was 0.1% (v / v).

[0088] Differentiated motor neurons (iPSNs) were obtained from iPSCs as listed above. The differentiation process was based on a previously reported method with minor modifications. 33,34 Briefly, iPSCs were seeded (30–40% confluent) in Matrigel-coated 100 mm dishes. Neuroepithelial induction was performed by replacing the basal medium with Stage 1 medium [47.5% IMDM (Iscove's Modified Dulbecco's Medium), 47.5% F12 medium, 1% NEAA (non-essential amino acids) (Life Technologies), 2% B27 (Invitrogen), 1% N2 (Invitrogen), 1% PSA (penicillin-streptomycin-amphotericin), 0.2 μM LDN193189 (Stemgent), 10 μM SB431542 (STEMCELL Technologies) and 3 μM CHIR99021 (Sigma-Aldrich)]. The medium was replaced every day for 6 days, after which the cells were detached from the plate using Accutase (STEMCELL Technologies). 6Cells were seeded into 3 mL of Stage 2 medium (Stage 1 medium supplemented with 0.1 μM All-trans RA (Sigma-Aldrich) and 1 μM SAG (Cayman Chemicals)) in 1000 μl of medium (cells / well). Cells were maintained in Stage 2 medium with daily medium changes until day 11 of the differentiation process. On day 12, stage 2 cell medium was removed and replaced with stage 3 medium [47.5% IMDM, 47.5% F12 medium, 1% NEAA, 2% B27, 1% N2, 1% PSA, 0.1 μM Compound E (Millipore; Cat. No.: 565790), 2.5 μM DAPT (Sigma-Aldrich), 0.1 μM db-cAMP (Millipore), 0.5 μM All-trans RA, 0.1 μM SAG, 20 ng / mL ascorbic acid, 10 ng / mL BDNF (STEMCELL Technologies), and 10 ng / mL GDNF (STEMCELL Technologies)]. This medium was replaced every 3 days until the end of the differentiation process. Typically, a minimum of 18 days is required to produce immature differentiated motor neurons, and 30 days of differentiation is the standard for producing mature differentiated spinal cord neurons. After these cells reach maturity, they can be maintained in culture for an additional 14-28 days.

[0089] Differentiated motor neurons were treated with compounds starting on day 15. Cells were treated in Matrigel-coated 6-well plates with stage 3 differentiation medium (see above) supplemented with compounds. Cells were treated with fresh medium containing compounds diluted in 0.1% DMSO every 3-4 days until full maturation was reached on day 32. The cells were harvested for analysis on day 32.

[0090] Cell viability. Patient-derived LCLs were cultured in a 96-well plate (approximately 10 4Cells were seeded in 1000 x 1000 cells / well) overnight and treated with compounds for 96 hours. Cell viability was measured using the CellTiter-Fluor™ Cell Viability Assay (Promega) following the manufacturer's protocol. iPSC cell viability was measured by seeding cells on Matrigel-coated 6-well plates (maintenance of iPSCs described above) with basal medium. After overnight incubation, the medium was replaced with fresh medium containing compound diluted in 0.1% DMSO. Cells were treated with compounds for 96 hours. Cell viability was measured using AlamarBlue™ Cell Viability Reagent (DAL1025, Thermo Fisher Scientific) following the manufacturer's protocol. iPSN cell viability was measured.

[0091] Measurement of RAN translation in HEK cells. HEK293T cells were cultured as described above. After reaching approximately 80% confluency, r(G4C2) 66- HEK293T cells were batch transfected in 100 mm dishes for 5 h using the Lipofectamine 3000 transfection system (Thermo Fischer) with 2.5 μg of plasmid encoding non-ATG-nanoluciferase and 1 μg of plasmid encoding SV40-Firefly luciferase (Life Technologies) according to the manufacturer's protocol. Cells were seeded in 384-well plates and incubated overnight. Compounds were treated for 24 h with a final DMSO concentration of less than 0.1%. RAN and classical translation were measured using the Dual-Luciferase® Reporter Assay System (Promega) according to the manufacturer's protocol. Experiments were performed as biological triplicates (n=3). Fluorescence intensity of untransfected cells was measured to determine background signal.

[0092] Measurement of C9orf72 and C9orf72 variant levels by RT-qPCR. LCLs and iPSCs were seeded in 6-well plates (approximately 10 6Cells) and incubated overnight at 37°C and 5% CO2. LCLs were then treated with compounds for 4 days without changing the medium, and patient-derived iPSCs were seeded at approximately 80% confluency and treated as described above. Treatment with G4C2-ASO or control-ASO (100 nM) was used as a control. ASO transfection was achieved using Lipofectamine RNAiMax (Life Technologies) according to the manufacturer's protocol. After 4 days of treatment (with either compounds or ASO), total RNA was extracted using Quick-RNA Miniprep Kit (Zymo Research). RNA was quantified by Nanodrop, and approximately 1 μg of total RNA was reverse transcribed using qScript (Quantbio) according to the manufacturer's guidelines. RT-qPCR was performed using Power SYBR Green Master Mix (Applied Biosystems) on a QuantStudio™ Real-Time PCR Instrument (Applied Biosystems). mRNA expression levels were normalized to GAPDH. See Table 2 for a list of primers used.

[0093] For iPSNs, cells were differentiated until day 15 according to the protocol outlined above. Starting on day 15, cells were supplemented with medium containing compounds in 0.1% DMSO every 3-4 days until day 32 of the differentiation process. RNA was extracted as described above and expression levels of C9orf72 variants were determined by RT-qPCR and normalized to GAPDH. See Table 2 for a list of primers used.

[0094] siRNA experiments. iPSCs were cultured as described in the "Cell culture" section. Briefly, iPSCs were seeded in 6-well Matrigel-coated plates and treated with compounds and siRNA for 4 days. On day 1, fresh medium was added to the cells and siRNA was transfected using Lipofectamine RNAiMax (Life Technologies) following the manufacturer's protocol. Cells were incubated at 37°C for 1 hour, then compounds were added to a final concentration of 50 nM (0.1% (v / v) DMSO). Cells were incubated for 48 hours, then medium was replaced and siRNA was re-transfected. After 1 hour of incubation, cells were treated with compounds and then incubated for another 48 hours. After a total of 96 hours of treatment, RNA was extracted and RT-qPCR was performed following the protocol outlined in "Measurement of C9orf72 and C9orf72 variant levels by RT-qPCR".

[0095] Transcriptome-wide studies by RNA-seq. Total RNA integrity was confirmed by Agilent 2100 Bioanalyzer RNA nano chip and its quantity was measured by Qubit2.0 fluorometer (Invitrogen). Library preparation was performed using the NEBNext Ultra II Directional RNA Kit (NEB, E7760) in combination with the NEBNext rRNA removal module (NEB, E6310) and the RNA fragmentation module (NEB, E6150S) according to the manufacturer's recommendations. Briefly, a total of 200 ng of RNA was first processed with ribosomal RNA removed and then randomly fragmented to achieve a range of 150-300 nucleotides. The fragmented RNA was randomly primed for the synthesis of the first strand, and the second strand was synthesized with dUTP. Thus, the USER enzyme (Uracil specific excision reagent) was used to preserve the information of these strands. cDNA was PCR amplified, equimolarly pooled onto a NextSeq 500 v2.5 flow cell, and sequenced using a 2 × 40 bp paired-end method. Exported fastq files were aligned using STAR. 35 The number of reads in specific regions was extracted using SAMtools. 36 Global differential gene expression analysis was performed using featureCounts and Deseq2. 37,38 .

[0096] Measurement of poly(GP) abundance by electrochemiluminescence. Meso Scale Discovery (MSD) Technology utilizes electrochemiluminescence to detect biomarkers such as poly(GP) in protein samples. All cells were seeded in 6-well plates. LCLs were diluted to 1 × 10 in 2 mL of RPMI. 6Cells / mL were seeded and treated with compounds for 4 days without changing the medium. Patient-derived iPSCs were seeded at approximately 80% confluency and treated as described above. For patient-derived iPSNs, compound treatment was initiated on day 15 of the differentiation process as previously described. Compounds were diluted in medium to a final concentration of 0.1% DMSO. After 4 days of compound treatment, cells were pelleted and proteins were extracted with CoIP buffer (50 mM Tris-HCL (pH 7.4), 300 mM NaCl, 5 mM EDTA, 1% Triton-X100, 2% sodium dodecyl sulfate, 0.01% protease and phosphatase inhibitors) for 5 minutes on ice. Proteins were then sheared by sonication (3 s intervals at 35% power for a total "on" interval time of approximately 20 s). Detergent was removed from the CoIP buffer using a Pierce™ Detergent Removal Spin Column 0.5 mL (Thermo Scientific) following the manufacturer's protocol. Protein samples were quantified using the Pierce™ MicroBCA Protein Assay Kit (Thermo Scientific).

[0097] Poly(GP) levels were measured by electrochemiluminescence sandwich immunoassay. MSD Gold 96-well small spot streptavidin SECTOR plates (MSD Technology) were incubated with 2 μg / mL of biotin antibody overnight at 4°C. The incubation wells were washed three times with 1×TBST (Tris-buffered saline containing 0.1% (v / v) Tween 20) and then blocked with 3% (w / v) BSA solution in 1×TBST for 1 h with shaking at room temperature. The wells were washed three times with 1×TBST and 80 μg of cell lysate was added to each well. The wells were incubated with lysate for 2 h with shaking at room temperature. After protein incubation, the wells were washed three times with 1×TBST and 4 μg / mL of Sulfo-labeled antibody was diluted in 3% BSA solution in 1×TBST and added to the wells. The wells were incubated at room temperature and covered with aluminum foil with shaking for 1 h. After incubation, the wells were washed three times with 1×TBST and 150 μL of 1×MSD ​​GOLD Read Buffer (MSD Technology) was added to the wells immediately prior to reading the plate. The plate was read using a SECTOR Imager (MSD Technology).

[0098] Western blotting. Protein samples were prepared as described for electrochemiluminescence sandwich immunoassay analysis. Approximately 20 μg of total protein was loaded onto a 4-20% Mini-PROTEAN® TGX™ precast protein gel (Bio-Rad) and run for 1 h at 130 V in Tris-glycine / SDS running buffer (25 mM Tris base, 190 mM glycine, 0.1% SDS, pH 8.3). After electrophoresis, proteins were transferred to a PVDF membrane using Tris-glycine transfer buffer (25 mM Tris base, 190 mM glycine, 20% methanol, pH 8.3). After transfer, the membrane was washed with 1× TBST and blocked with a solution containing 5% (w / v) milk in 1× TBST for 30 min at room temperature with shaking. The membrane was then incubated overnight at 4°C in 1xTBST containing 5% milk with 1:3000 C9orf72 primary antibody (GeneTex, GTX119776). The membrane was washed three times with 1xTBST and incubated with 1:2000 anti-mouse IgG horseradish peroxidase secondary antibody conjugate (Cell Signaling Technology) at room temperature for 1 hour with gentle shaking in 1xTBST. The membrane was then washed three times with 1xTBST and protein expression was quantified using SuperSignal West Pico Plus chemiluminescent substrate (Life Technologies) according to the manufacturer's protocol and film exposed. To quantify β-actin expression, the membrane was washed with 1xTBST and stripped with 1x stripping buffer (200mM glycine, 1% (v / v) Tween20, 0.1% (w / v) SDS, pH 2.2). After stripping, the membrane was washed with 1×TBST and blocked again with 5% milk in 1×TBST for 30 min at room temperature with shaking, then incubated overnight at 4° C. with β-actin primary antibody (Cell Signaling Technology) at 1:3000 in 1×TBST containing 5% milk.The membrane was washed with 1× TBST and incubated with anti-mouse IgG horseradish peroxidase secondary antibody conjugate (Cell Signaling Technology, Inc.) at 1:5,000 in 1× TBST for 1 h at room temperature. β-actin protein expression was quantified as previously described.

[0099] In vivo methods Therapeutic Efficacy in c9ALS / FTD Mouse Model. All animal studies were approved by the Scripps Florida Institutional Animal Care and Use Committee.

[0100] PWR500 BAC mice. A total of 20 age- and sex-matched mice (12 + / +PWR500 [5 males and 7 females] and 8 WT [4 males and 4 females]) aged 18-21 years were used in the therapeutic efficacy study (Table 4). Mice were treated with a single bolus injection of 33 nmol of Compound 2 formulated in 1% (v / v) DMSO / 99% water administered by intracerebroventricular injection (ICV). Mice were euthanized 3 weeks after injection and tissues were harvested for study.

[0101] Measurement of C9orf72 variants by RT-qPCR. Postmortem brain tissue was harvested and sliced ​​along the sagittal plane at the midline. The left hemisphere was frozen for RNA and protein analysis. Frozen brain tissue was homogenized in 300 μL of Tris-EDTA buffer containing 2× protease and phosphatase inhibitors at a 1:5 w / v ratio. RNA was extracted from half of the homogenized tissue solution (150 μL) using Triazole LS (added to the homogenized tissue at a 1:3 ratio). The Triazole / tissue solution was centrifuged at 16,000 rpm for 15 min and the supernatant was collected. An equal volume of 100% ethanol was added to the supernatant and RNA was purified using the Direct-zol RNA kit (Zymo Research) according to the manufacturer's protocol. RT-qPCR was then performed as described above. mRNA expression levels were normalized to mouse β-actin. See Table 2 for a list of primers.

[0102] Measurement of poly(GP) abundance by electrochemiluminescence. Postmortem brain tissue was harvested and sliced ​​along the sagittal plane at the midline. The left hemisphere was frozen for RNA and protein analysis. As was done for tissue RNA analysis, frozen brain tissue was homogenized in 300 μL of Tris-EDTA buffer containing 2× protease and phosphatase inhibitors at a 1:5 w / v ratio. Half of the homogenized tissue (150 μL) was mixed with 2× lysis buffer (50 mM Tris (pH 7.4), 250 mM NaCl, 2% (v / v) Triton X-100 and 4% (w / v) SDS) and sonicated at 30% and 1 s on / off intervals for a total of 15 s. Detergent was removed using a Pierce™ Detergent Removal Spin Column 0.5 mL (Thermo Scientific) according to the manufacturer's protocol. Protein concentration was then measured by BCA assay (Pierce Biotechnology), and poly(GP) was measured as described above for the electrochemiluminescence sandwich immunoassay.

[0103] Immunohistochemistry (IHC). Postmortem brain tissue was harvested and sliced ​​along the sagittal plane at the midline. The right hemisphere was stored in 10% neutral buffered formalin for 48 hours. Tissue processing, embedding and sectioning were then performed by Scripps Florida Histology Core. Formalin-fixed tissue was processed in a Sakura Tissue-Tek VIP 5 paraffin processor. Tissue was first embedded in paraffin, sectioned at 4 μM and then mounted on positively charged slides. Slides were stained with primary antibodies (see below) using the Leica BOND-MAX platform. Slides were then subjected to a Leica Refine detection kit containing secondary polymer, DAB chromogen and counterstain. Slides were dehydrated in graded alcohols and cleared in xylene before coverslipping with permanent mounting medium (Cytoseal 60; Thermo Scientific).

[0104] Antibodies: NeuN (1:2000, RRID:AB_177621, Millipore); PolyGA (1:2000, MABN889, Millipore); PolyGP (1:5000, ABN455, Millipore); Calbindin (1:5000, RRID:AB_476894, Millipore); TDP-43 (1:2000, RRID:AB_615042, Proteintech).

[0105] RNA fluorescence in situ hybridization (FISH) with immunofluorescence (IF). Postmortem brain tissue was excised and sliced ​​along the sagittal plane at the midline. The right hemisphere was flash frozen under liquid nitrogen with optimal cutting temperature (OCT) compound in 2-methylbutane. Frozen tissue was sectioned (10 μM) using a cryostat, and slides were stained as previously described. 39Briefly, frozen sections were fixed in 4% paraformaldehyde in 1xDPBS for 20 min, then incubated in ice-cold 70% ethanol at 4°C for 30 min. Once fixed, slides were incubated in 40% formamide in 2xSSC buffer at room temperature for 10 min. Slides were blocked in 1x hybridization buffer (40% formamide, 2xSSC buffer, 20 μg / mL BSA, 100 mg / mL dextran sulfate, 250 μg / mL tRNA, and 2 mM vanadyl sulfate) at 55°C for 30 min. Slides were then incubated with 200 ng / mL FISH probe (Table 1) in 1x hybridization buffer at 55°C for 3 h. After hybridization, slides were washed with 2xSSC buffer (3 times) and 40% formamide in 1xDPBS. Slides were then co-stained with NeuN (Sigma: MAB377B) as follows: Tissues were permeabilized with 0.5% (v / v) Triton X-100 in 1xDPBS for 15 min at 4°C. The tissues were then blocked with 2% (v / v) goat serum in 1xDPBS for 1.5 h at 4°C. Slides were incubated overnight at 4°C with NeuN (1:500, MAB377B, Sigma) diluted in 2% goat serum in 1xDPBS. After incubation with the primary antibody, slides were washed three times with 1xDPBS and incubated with secondary antibody (donkey anti-goat IgG conjugated to Alexa Fluor 488; AbCam) (diluted 1:500 in 1xDPBS) for 1 h at room temperature. Slides were then washed three times with 1x DPBS and quenched with 0.25% Sudan Black B (Millipore) diluted in 70% ethanol. After the slides were completely dried, they were mounted with mounting medium containing DAPI (Invitrogen) and imaged using a 60x objective.

[0106] Calculation method Parameterization of the ALS compound of formula I. From previous studies, all Amber force field parameters for the ALS compound of formula I were obtained (table below). 31Force field parameters for NH-modified PEG linkers (NH-PEG; below) were prepared as previously described. 40~42 . Amber GAFF force field 43 Atom types were determined using the multi-molecule RESP charge fitting protocol. 44,45 The RESP charges were obtained according to the following formula. These molecules were optimized and the 6-31G* basis set (here, Gaussian09 was used to perform these calculations). 46 The electrostatic potential was calculated at the HF level as a set of grid points using the NMR method.

[0107] Binding Studies. The binding mode of the ALS compounds of Formula I to the r(G4C2) repeat model was determined by previously established methods. 31 The lowest energy binding mode was used to homology model the ALS compound of Formula 1 bound to a double-stranded model of the r(G4C2) repeat.

[0108] Explicit solvent molecular dynamics (MD) simulations. Explicit water MD simulations were performed to find the optimal binding conformation. The initial coordinates for the MD simulations were extracted from the homology modeling results, and 21 Na + ion 47 The system was made neutral by adding TIP3P water molecules to the system such that all atoms of the RNA and 3 were at least 8.0 Å away from the edge of the simulation box. Long-range electrostatic interactions were calculated using the Particle Mesh Ewald method. 48 The temperature and pressure were maintained as 300 K and 1 bar throughout the simulation, using Langevin dynamics and a Berendsen barostat. Three independent MD simulations spanning 500 ns with a time step of 1 fs were completed. A total of 1.5 μs of combined MD trajectories were generated and used in the cluster analysis.

[0109] Cluster analysis and MM-PBSA calculations. Cluster analysis was performed to determine the structural population using CPPTRAJ, which groups similar conformations together in a given trajectory file by root mean square deviation (RMSD) analysis. A density-based scanning algorithm was used with an RMSD cutoff distance of 1.3 Å to form the clusters. Three stable binding conformations were revealed from the cluster analysis. MM-PBSA analysis was performed for each cluster to determine the lowest binding free energy state. The MMPBSA.py module of Amber16 was used and the relative binding free energy results are presented. The binding conformation with the lowest binding energy was selected as the most stable binding conformation.

[0110] Synthesis method Abbreviations: Ac2O (acetic anhydride), CDCl3 (chloroform-d), CD3OD (methanol-d4), Cs2CO3 (cesium carbonate), DIPEA (N,N-diisopropylethylamine), DCM (dichloromethane), DMF (N,N-dimethylformamide), DMSO (dimethylsulfoxide), EDC (N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride), Et3N (triethylamine), EtOAc (ethyl acetate), HCl (hydrochloric acid), H2O (water), HOBt (1-hydroxybenzotriazole) (HPLC), HPLC (High Performance Liquid Chromatography), K2CO3 (Potassium Carbonate), LiCl (Lithium Chloride), MALDI (Matrix Assisted Laser Desorption / Ionization), MeOH (Methanol), NaH (Sodium Hydride), NaHCO3 (Sodium Bicarbonate), NaI (Sodium Iodide), NaOMe (Sodium Methoxide), Na2SO4 (Sodium Sulfate), NMR (Nuclear Magnetic Resonance), PEG (Polyethylene Glycol), TFA (Trifluoroacetic Acid), THF (Tetrahydrofuran), TLC (Thin Layer Chromatography).

[0111] Summary. Reagents and solvents were purchased from standard suppliers and used without further purification. Reactions were monitored by TLC. Spots were visualized using UV light or phosphomolybdic acid or ninhydrin staining. Products were purified by HPLC (Waters 2489 pump and 1525 detector) using a pre-packed silica gel column (Agela Technologies) or a SunFire® Prep C18 OBD™ 5 μM column (19×150 mm) at a flow rate of 5 mL / min. Compound purity was analyzed by HPLC using a SunFire® C18 3.5 μM column (4.6×150 mm) at a flow rate of 1 mL / min. 400 UltraShield™ (Bruker) ( 1 H is 400MHz and 13 C 100MHz) or Ascend 600 (Bruker) 1 H is 600MHz and 13 NMR spectra were measured using a 150 MHz C laser (150 MHz for C). Chemical shifts were measured using 1 H: trimethylsilane (TMS); 13 In C, the mass spectra are expressed in ppm relative to residual solvent. Coupling coefficients (J values) are reported in Hz. High-resolution mass spectra were recorded on a 4800 Plus MALDI TOF / TOF Analyzer (Applied Biosystems) using α-cyano-4-hydroxycinnamic acid matrix and TOF / TOF calibration mixture (AB Sciex Pte.) or on an Agilent 1260 Infinity LC system coupled to an Agilent 6230 TOF (HR-ESI) equipped with a Poroshell 120 EC-C18 column (Agilent, 50 mm × 4.6 mm, 2.7 μM).

[0112] Synthesis experimental procedure Carbazole compounds of formula II, i.e., r(G4C2) expThe synthesis of the conjugated compounds followed established experimental routes. Conjugation of the carbazole of formula II to the RNase recruiting moiety of formula IIIA is achieved by attaching ethyl 4-bromobutyrate to the carbazole of formula II where X is OH, hydrolyzing the ethyl ester group to form a carboxylic acid group, and carbodiimide amide coupling of the carboxylic acid group to the amine group of the amine PEG RNase recruiting moiety (formula IIIA) where the amine PEG group is attached to the OR' group of formula IIIA by forming a sodium phenoxide of the OR' group of formula IIIA and coupling of the phenoxide group to ω-bromo-α-tosyl PEG. The synthesis scheme of the ALS compound of formula I where n is 2 and R is methyl is shown below as Scheme I. [ka]

[0113] References 1 Bernat, V. & Disney, Matthew D. RNA Structures as Mediators of Neurological Diseases and as Drug Targets. Neuron 87, 28-46, doi:https: / / doi.org / 10.1016 / j.neuron.2015.06.012 (2015). 2 Todd, PK & Paulson, HL RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol 67, 291-300, doi:10.1002 / ana.21948 (2010). 3 Rohilla, K. J. & Gagnon, K. T. RNA biology of disease-associated microsatellite repeat expansions. Acta Neuropathologica Communications 5, 63, doi:10.1186 / s40478-017-0468-y (2017). 4 DeJesus-Hernandez, M. et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron 72, 245-256, doi:https: / / doi.org / 10.1016 / j.neuron.2011.09.011 (2011). 5 Renton, Alan E. et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron 72, 257-268, doi:https: / / doi.org / 10.1016 / j.neuron.2011.09.010 (2011). 6 Liang, X.-H., Sun, H., Nichols, J. G. & Crooke, S. T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol Ther 25, 2075-2092, doi:10.1016 / j.ymthe.2017.06.002 (2017). 7 Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35, 687-700, doi:10.1093 / nar / gkl1071 (2007). 8 McMahon, B. M. et al. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev 12, 65-70, doi:10.1089 / 108729002760070803 (2002). 9 Schoch, K. M. & Miller, T. M. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron 94, 1056-1070, doi:10.1016 / j.neuron.2017.04.010 (2017). 10 Swayze, E. et al. Kinetics of ASO Distribution and Pharmacodynamics in the CNS after an Intrathecal Bolus Dose in Rat (S38.008). Neurology 86, S38.008 (2016). 11 Wang, Z.-F. et al. The Hairpin Form of r(G4C2)exp in c9ALS / FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules. Cell Chemical Biology 26, 179-190.e112, doi:https: / / doi.org / 10.1016 / j.chembiol.2018.10.018 (2019). 12 Su, Z. M. et al. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD / ALS. Neuron 83, 1043-1050, doi:10.1016 / j.neuron.2014.07.041 (2014). 13 Beck, J. et al. Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. The American Journal of Human Genetics 92, 345-353, doi:https: / / doi.org / 10.1016 / j.ajhg.2013.01.011 (2013). 14 van Blitterswijk, M. et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. The Lancet Neurology 12, 978-988, doi:https: / / doi.org / 10.1016 / S1474-4422(13)70210-2 (2013). 15 Ash, P. E. et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD / ALS. Neuron 77, 639-646, doi:10.1016 / j.neuron.2013.02.004 (2013). 16 Mori, K. et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta neuropathologica 126, 881-893, doi:10.1007 / s00401-013-1189-3 (2013). 17 Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD / ALS. Science 339, 1335-1338, doi:10.1126 / science.1232927 (2013). 18 Zu, T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 110, E4968-4977, doi:10.1073 / pnas.1315438110 (2013). 19 Gendron, T. F. et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD / ALS. Acta neuropathologica 126, 829-844, doi:10.1007 / s00401-013-1192-8 (2013). 20 Chew, J. et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener 14, 9, doi:10.1186 / s13024-019-0310-z (2019). 21 Gendron, T. F., Belzil, V. V., Zhang, Y. J. & Petrucelli, L. Mechanisms of toxicity in C9FTLD / ALS. Acta neuropathologica 127, 359-376, doi:10.1007 / s00401-013-1237-z (2014). 22 Gendron, T. F. et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Science translational medicine 9, doi:10.1126 / scitranslmed.aai7866 (2017). 23 Han, Y. et al. Structure of Human RNase L Reveals the Basis for Regulated RNA Decay in the IFN Response. Science 343, 1244, doi:10.1126 / science.1249845 (2014). 24 Thakur, C. S. et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proceedings of the National Academy of Sciences 104, 9585, doi:10.1073 / pnas.0700590104 (2007). 25 Silverman, R. H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 81, 12720-12729, doi:10.1128 / jvi.01471-07 (2007). 26 Costales, M. G. et al. Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proc Natl Acad Sci U S A 117, 2406-2411, doi:10.1073 / pnas.1914286117 (2020). 27 Costales, M. G., Matsumoto, Y., Velagapudi, S. P. & Disney, M. D. Small Molecule Targeted Recruitment of a Nuclease to RNA. Journal of the American Chemical Society 140, 6741-6744, doi:10.1021 / jacs.8b01233 (2018). 28 Costales, M. G., Suresh, B., Vishnu, K. & Disney, M. D. Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA. Cell chemical biology 26, 1180-1186.e1185, doi:10.1016 / j.chembiol.2019.04.008 (2019). 29 Liu, X. et al. Targeted Degradation of the Oncogenic MicroRNA 17-92 Cluster by Structure-Targeting Ligands. Journal of the American Chemical Society, doi:10.1021 / jacs.9b13159 (2020). 30 Li, Y. & Disney, M. D. Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype. ACS Chem Biol 13, 3065-3071, doi:10.1021 / acschembio.8b00827 (2018). 31 Wang, Z. F. et al. The hairpin form of r(G4C2)exp in c9ALS / FTD is repeat-associated non-ATG translated and a target for bioactive small molecules. Cell chemical biology 26, 179-190.e112, doi:10.1016 / j.chembiol.2018.10.018 (2019). 32 Angelbello, A. J. & Disney, M. D. Bleomycin can cleave an oncogenic noncoding RNA. Chembiochem 19, 43-47, doi:10.1002 / cbic.201700581 (2018). 33 Moore, S. et al. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS / FTD. Acta Neuropathol 138, 49-65, doi:10.1007 / s00401-019-01999-w (2019). 34 Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56-61, doi:10.1038 / nature14973 (2015). 35 Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21, doi:10.1093 / bioinformatics / bts635 (2013). 36 Li, H. et al. The Sequence Alignment / Map format and SAMtools. Bioinformatics 25, 2078-2079, doi:10.1093 / bioinformatics / btp352 (2009). 37 Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930, doi:10.1093 / bioinformatics / btt656 (2014). 38 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186 / s13059-014-0550-8 (2014). 39 Liu, Y. et al. C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS / FTD. Neuron 90, 521-534, doi:10.1016 / j.neuron.2016.04.005 (2016). 40 Childs-Disney, J. L. et al. Structure of the Myotonic Dystrophy Type 2 RNA and Designed Small Molecules That Reduce Toxicity. ACS Chem. Biol. 9, 538-550, doi:10.1021 / cb4007387 (2014). 41 Childs-Disney, J. L. et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun. 4, doi:10.1038 / ncomms3044 (2013). 42 Costales, M. G. et al. Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proceedings of the National Academy of Sciences 117, 2406, doi:10.1073 / pnas.1914286117 (2020). 43 Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field (vol 25, pg 1157, 2004). J. Comput. Chem. 26, 114-114, doi:10.1002 / jcc.20145 (2005). 44 Bayly, C. I., Cieplak, P., Cornell, W. D. & Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the Resp Model. J. Phys. Chem. 97, 10269-10280 (1993). 45 Cornell, W. D., Cieplak, P., Bayly, C. I. & Kollman, P. A. Application of RESP charges to calculate conformational energies, hydrogen-bond energies, and free-energies of solvation. J. Am. Chem. Soc. 115, 9620-9631 (1993). 46 Gaussian 09 v. Revision A.02 (Gaussian, Inc., Wallingford, CT, 2016). 47 Sangster, M. J. L. & Atwood, R. M. Interionic potentials for alkali halides. II. Completely crystal independent specification of Born-Mayer potentials. Journal of Physics C: Solid State Physics 11, 1541-1555, doi:10.1088 / 0022-3719 / 11 / 8 / 015 (1978). 48 TE Cheatham, I., JL Miller, T. Fox, TA Darden, and PA Kollman. Molecular Dynamics Simulations on Solvated Biomolecular Systems: The Particle Mesh Ewald Method Leads to Stable Trajectories of DNA, RNA, and Proteins. J Am Chem Soc 117, 4193-4194 (1995).

[0114] Various Descriptions Although the present invention has been described in conjunction with a detailed description thereof, the above description is for illustrative purposes only and is not intended to limit the scope of the invention, which is defined by the scope of the appended claims. From the foregoing, it will therefore be understood that specific non-limiting embodiments of the invention have been described herein for illustrative purposes, but that various modifications can be made without departing from the spirit and scope of the invention. Other aspects, advantages and modifications are within the scope of the following claims, and the invention is not limited except by the scope of the appended claims.

[0115] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a conditional or negative limitation that removes any subject matter from its genus, regardless of whether the excised subject matter is specifically described herein.

[0116] The terms and expressions that have been used are used as terms of description and not as terms of limitation, and there is no intention in the use of such terms and expressions to exclude any equivalent features shown and described or portions thereof, recognizing that various modifications are possible within the scope of the invention as claimed. Thus, although the present invention has been specifically disclosed by various non-limiting and / or preferred non-limiting embodiments and optional features, it is understood that any and all modifications and variations of the concepts disclosed herein that may be resorted to by those skilled in the art are considered to be within the scope of the invention as defined by the appended claims.

[0117] All patents, publications, scientific articles, websites, and other literature and reference materials or mentioned herein are indicative of the level of skill of those skilled in the art to which this invention pertains, and each such reference and material is incorporated herein by reference to the same extent as if fully and verbatim herein. The right is reserved to physically incorporate into this specification any and all materials and information from any such patents, publications, scientific articles, websites, electronically available information, textbooks, or other reference materials or literature.

[0118] All references cited herein are incorporated by reference as if fully set forth herein in their entirety.

[0119] [Table 1] [Table 2] JPEG2024541938000009.jpg151159 [Table 3] [Table 4]

Table 5

Claims

1. Hexanucleotide repeat-expanded RNA r(G 4 C 2 ) exp to Formula I: [Case 1] (In the formula, R is hydrogen or a C1-C3 alkyl group, preferably a methyl group, more preferably hydrogen; Y is -COO, -CH 2 -O-, preferably -CH 2 -O-, n is an integer from 1 to 6, preferably from 2 to 4, and more preferably 2.

23. A method comprising contacting an ALS compound comprising a pyridocarbazole moiety linked to an RNase moiety, and pharma- ceutically acceptable salts thereof, according to claim 22.

2. By the contact, the r(G 4 C 2 ) exp The method of claim 1, wherein the antibody is bound to and / or complexed with the antibody.

3. The r(G 4 C 2 ) exp is r(G 4 C 2 ) m The method according to any one of claims 1 to 2, wherein m is at least 20.

4. r (G 4 C 2 ) m The method of any one of claims 1 to 3, wherein m is an abnormal number of repeats, m being at least 20 to 1000.

5. The r(G 4 C 2 ) exp The method according to any one of claims 1 to 4, wherein the repeat RNA hairpin structure is a repeat RNA hairpin structure.

6. r (G 4 C 2 ) expThe method according to any one of claims 1 to 5, wherein said gene is present in a cell.

7. The cell contains chromosome 9 open reading frame 72 (C9orf72) and r(G 4 C 2 ) exp The method of claim 6, wherein said C9orf72 gene is located in intron 1.

8. The method of any of claims 6 and 7, wherein the cells are patient-derived cells.

9. The method according to any one of claims 6 to 8, wherein the cells are incubated with the ALS compound according to claim 1.

10. 10. The method of claim 9, wherein the cells are HEK293T cells, patient-derived lymphoblastoid cells, induced pluripotent stem cells (c9 iPSC cells), iPSC-derived spinal cord neurons (c9 iPSNs).

11. The method of claim 10, wherein the cells are c9ALS / FTD BAC cells in a transgenic mouse model.

12. The ALS compound is 4 C 2 ) exp The method according to any one of claims 6 to 11, wherein the method reduces RNA translation.

13. The ALS compound is 4 C 2 ) exp The method of claim 12, wherein the RNA translation of the gene is inhibited.

14. The method of any one of claims 6 to 13, wherein the ALS compound does not inhibit transcription of C9orf72.

15. The method of any one of claims 6 to 14, wherein the ALS compound reduces the number of nuclear foci.

16. The method of any one of claims 6 to 15, wherein the ALS compound alleviates a defect in nuclear transport.

17. The method of any one of claims 6 to 16, wherein the ALS compound promotes degradation of the repeat expansion.

18. 13. A pharmaceutical composition comprising a pharma- ceutically acceptable carrier and an ALS compound according to formula I of claim 1.

19. 20. The pharmaceutical composition of claim 18, wherein the pharma- ceutically acceptable carrier comprises an excipient suitable for a selected route of administration of the ALS compound.

20. The amount of the ALS compound is G 4 C 2 A pharmaceutical composition according to any of claims 18 to 19, providing an effective dose of said ALS compound for the treatment of a disease caused by repeat expansion, preferably ALS / FTD disease.

21. 13. A method for the treatment of ALS / FTD disease comprising administering to a patient having said disease an effective amount of an ALS compound of claim 1.

22. A method for the treatment of ALS / FTD disease comprising the administration of a pharmaceutical composition according to any one of claims 18 to 20 to a patient suffering from said disease.

23. The method for treatment according to any one of claims 21 to 22, wherein the ALS / FTD disease is amyotrophic lateral sclerosis.

24. 24. The method of claim 23, wherein the step of administering comprises oral, intramuscular, intravenous or intrathecal administration of the ALS compound in a pharma- ceutically acceptable solvent.

25. 25. The method of claim 24, wherein the ALS compound in a pharma- ceutically acceptable solvent is a pharmaceutical composition.

26. 26. The method of claim 25, wherein the pharmaceutical composition comprises a pharma- ceutically acceptable excipient suitable for a selected route of administration, the excipient being compatible with the ALS compound.

27. Formula I: [Case 2] (In the formula, R is hydrogen or a C1-C3 alkyl group, preferably a methyl group, more preferably hydrogen; Y is -COO- or -CH 2 -O-, preferably -CH 2 -O-, n is an integer from 1 to 6, preferably from 2 to 4, and more preferably 2.

23. A composition comprising the ALS compound of claim 22 and pharma- ceutically acceptable salts thereof.